



**TECHNICAL DOCUMENT
FOR
TESTING AND INVESTIGATIONS**

Implementing the *WADA International Standard for Testing and Investigations*

Version 1.0, in effect as from 1 January 2021

TABLE OF CONTENTS

INTRODUCTION	3
TITLE I TEST PLANNING	4
ARTICLE 1 TESTING DISTRIBUTION PLAN	4
ARTICLE 2 REGISTERED TESTING POOL	5
ARTICLE 3 WHEREABOUTS INFORMATION	6
ARTICLE 4 WHEREABOUTS INFORMATION IN TEAM SPORTS	9
TITLE II SAMPLE COLLECTION'S PROCEDURE	9
ARTICLE 5 NOTIFICATION OF ATHLETE	9
ARTICLE 6 REQUIREMENTS FOR NOTIFICATION OF ATHLETES	11
TITLE II SAMPLE COLLECTION SESSION	16
ARTICLE 7 PREPARING FOR THE SAMPLE COLLECTION SESSION	16
ARTICLE 8 CONDUCTING THE SAMPLE COLLECTION SESSION	18
TITLE IV SECURITY, POST-TEST ADMINISTRATION PROCEDURE, TRANSPORT AND OWNERSHIP OF SAMPLES	21
ARTICLE 9 REQUIREMENTS	21
ARTICLE 10 TRANSPORT OF SAMPLES AND DOCUMENTATION	21
ARTICLE 11 OWNERSHIP OF SAMPLES	22
ANNEX A – MODIFICATIONS FOR ATHLETES WITH IMPAIRMENTS	23
ANNEX B – MODIFICATIONS FOR ATHLETES WHO ARE MINORS	25
ANNEX C - COLLECTION OF URINE SAMPLES	27
ANNEX D – COLLECTION OF BLOOD SAMPLES	30
ANNEX E – URINE SAMPLES – INSUFFICIENT VOLUME	33
ANNEX F – URINE SAMPLES THAT DO NOT MEET THE REQUIREMENT FOR SUITABLE SPECIFIC GRAVITY FOR ANALYSIS	35
ANNEX I – COLLECTION, STORAGE AND TRANSPORT OF BLOOD ATHLETE BIOLOGICAL PASSPORT SAMPLES	40
DEFINITIONS	44

INTRODUCTION

The *Technical Document for Testing and Investigations* (hereinafter “TD_TI”) implements the *WADA International Standards for Testing and Investigations* (hereinafter “ISTI”) and it is deemed to form an integral and material part of the NADO Italia’s *Anti-Doping Sports Code* (hereinafter “ADSC”).

Interpretation

Unless otherwise specified, references to Sections and Articles are references to Sections and Articles of the TD_TI.

The Annexes to the TD_TI have the same mandatory status as the rest of the Document.

Terms used in this TD_TI that are defined terms from the *Code* and from the *ADSC* are italicized. Terms that are defined in this or another *WADA International Standard* are underlined.

General Principle

Like the *ADSC*, this TD_TI has been drafted giving consideration to the principles of proportionality, human rights, and other applicable legal principles. It shall be interpreted and applied in that light.

TITLE I TEST PLANNING

ARTICLE 1 TESTING DISTRIBUTION PLAN

- 11 NADO Italia, through the Anti-Doping Controls Committee (hereinafter the “ADCC”) plans and implements an Intelligent Testing Program which is proportionated to the risk of doping and that is effective to detect and to deter such practices.
- 12 In order to increase the effectiveness of NADO Italia’s testing program, the ADCC annually develops and approves the Technical Document “Risk Assessment” for sports and disciplines subject of its Testing Distribution Plan (“TDP”).
- 13 The Risk Assessment and the TDP are developed according to the relevant WADA’s documents (e.g. “International Standard for Testing and Investigations” – “ISTI”, “Guidelines for Implementing an Effective Testing Programme” and “TDSSA”).
- 14 The TDP is monitored, assessed and, if necessary, amended and updated on a regular basis as a result of possible changes in anti-doping circumstances and strategies.
- 15 Test distribution planning is an ongoing process, not a static one. NADO Italia shall review the TDP regularly during the year/cycle and shall adapt it, as necessary, to reflect new information gathered and intelligence developed, and to take into account Testing conducted by other Anti-Doping Organizations.
- 16 The ADCC develops a written strategy for retention of Samples and the documentation relating to the collection of such Samples so as to enable the further analysis of such Samples at a later date in accordance with *Code* Articles 6.5 and 6.6. Such strategy shall comply with the requirements of the International Standard for Laboratories and the International Standard for the Protection of Privacy and Personal Information and shall take into account the purposes of analysis of Samples set out in *Code* Article 6.2.
- 17 To implement the TDP, the ADCC selects the *Athletes* who are to undergo *Sample* collection procedures, according to the *Target Testing* and Random Selection method.
- 18 Once the *Athletes* to be subject to testing have been identified and the method of testing has been defined, the ADCC shall arrange for In-Competition or Out-of-Competition Testing to be conducted.
- 19 Testing takes place between 6 a.m. and 11 p.m. unless (i) the *Athlete* included in the national “*Registered Testing Pool*” stipulates a 60-minute timeslot from 5 a.m. or, (ii) valid grounds exist for Testing overnight (i.e., between 11 p.m. and 6 a.m.). Moreover, the fundamental principle set out in WADA Code (the “Code”) Article 5.2 is that an *Athlete* may be required to provide a *Sample* at any time and at any place by NADO Italia. Accordingly, an *Athlete* may not refuse to submit to *Sample* collection on the basis that such Testing is not provided for in the NADO Italia’s Test Distribution Plan and/or is not being conducted between 6 a.m. and 11 p.m., and/or that the *Athlete* does not meet the relevant selection criteria for Testing or otherwise should not have been selected for Testing.

- 1.10 NADO Italia, through the ADCC, shall coordinate their Testing efforts with the efforts of other Anti-Doping Organizations with overlapping Testing Authority, in order to maximize the effectiveness of those combined efforts, to avoid unnecessarily repetitive Testing of particular Athletes and to ensure Athletes competing at International Events are suitably tested in advance.
- 1.11 All Testing shall be No Advance Notice Testing, save in exceptional and justifiable circumstances set out in ISTI Article 5.3.1 and Article 5.3.7.
- 1.12 The *Athlete's* Support Personnel or any other person having a conflict of interests may not be involved in the (i) planning of Testing, (ii) selection of *Athletes* or (iii) phase of Testing implementation.

ARTICLE 2 REGISTERED TESTING POOL

- 2.1 The *Registered Testing Pool* ("RTP") includes *Athletes* that are subject to the greatest amount of Testing and are therefore required to provide whereabouts information in accordance with the provisions of the Article 3 here below and with ISTI Article 4.8.6. *Athletes* in the RTP are subject to *Code* Article 2.4.
- 2.2 The NSF/ASD/PSE shall be required to provide full support to NADO Italia during the collection of Whereabouts Information regarding *Athletes* falling under their jurisdiction.
- 2.3 The inclusion of an *Athlete* in the RTP implies compliance with whereabouts requirements as laid down by Article here below.
- 2.4 NADO Italia shall conduct Out-of-Competition Testing on *Athletes* included in its RTP using the *Athlete's* Whereabouts information. Testing shall not be limited to the 60-minute time slot provided by the *Athlete*. To ensure Out-of-Competition Testing is unpredictable to the *Athlete*, the ADCC shall also consider other whereabouts information provided e.g., regular activities to test the *Athlete*.
- 2.5 *Athletes* under the Testing Authority of NADO Italia and of an International Federation should only be in one *Registered Testing Pool* and therefore shall only file one set of whereabouts information. If the *Athlete* is included in the International Federation's RTP and in the NADO Italia's RTP, then each of them shall notify the *Athlete* that they are in its pool. Prior to doing so, however, they shall agree between themselves to whom the *Athlete* shall provide their Whereabouts Filings, and that Anti-Doping Organization shall be the whereabouts custodian. Each notice sent to the *Athlete* shall specify that they shall provide their Whereabouts Filings to that Anti-Doping Organization only (and it will then share that information with the other, and with any other Anti-Doping Organizations having authority to conduct Testing on that *Athlete*).
- 2.6 NADO Italia notifies each *Athlete* designated for inclusion in its RTP, at least, of the following: the fact that they have been included in its RTP with effect from a specified date in the future; the whereabouts requirements with which they shall therefore comply; the Consequences if they fail to comply with those whereabouts requirements; and that they may also be tested by other

Anti-Doping Organizations with authority to conduct Testing. NADO Italia gives to each *Athlete* included in its RTP a registered e-mail, for formal notice purposes.

- 2.7 *Athlete* who has been included in a RTP shall continue to be subject to the *Code* Article 2.4 Whereabouts Requirements unless and until: a) they have been given written notice by NADO Italia that put them in its RTP that they are no longer meet the criteria for inclusion in the RTP; or b) they retire from Competition in the sport in question in accordance with the applicable rules and gives written notice to that effect to each Anti-Doping Organization that put them in its RTP.

ARTICLE 3 WHEREABOUTS INFORMATION

- 3.1 *Athletes* included in the RTP shall be required to provide quarterly thorough and accurate personal information concerning his/her whereabouts during the relevant period so that he/she may be always located for the purposes of No Advanced Notice Testing during such period. NADO Italia reviews *Athletes* Whereabouts Filings to ensure they are submitted in accordance with the following provisions.

In detail:

- FIRST QUARTER (JANUARY/FEBRUARY/MARCH): Whereabouts Information must be notified by the *Athlete* in advance or within and not later than **15 December**, failing which disciplinary proceedings according to the document “Results Managements Procedure_First Instance Proceeding and Appeals”;
- SECOND QUARTER (APRIL/MAY/JUNE): Whereabouts Information must be notified by the *Athlete* in advance or within and not later than **15 March**, failing which disciplinary proceedings according to the document “Results Managements Procedure_First Instance Proceeding and Appeals”;
- THIRD QUARTER (JULY/AUGUST/SEPTEMBER): Whereabouts Information must be notified by the *Athlete* in advance or within and not later than **15 June**, failing which disciplinary proceedings according to the document “Results Managements Procedure_First Instance Proceeding and Appeals”;
- FOURTH QUARTER (OCTOBER/NOVEMBER/DECEMBER): Whereabouts Information must be notified by the *Athlete* in advance or within and not later than **15 September**, failing which disciplinary proceedings according to the document “Results Managements Procedure_First Instance Proceeding and Appeals”.

It is understood that if an *Athlete* is included in the RTP during a quarter that has already started (e.g. he/she is notified of his/her inclusion in the RTP on 15 July), then he/she shall be required to provide such thorough and accurate Whereabouts Information as to complete the relevant quarter starting from the day specified by NADO Italia and proceed with the completion of the following quarters according to the time schedule and conditions as outlined in Article 3.2 here above.

Whereabouts Information shall be provided through *ADAMS*.

- 3.2** If an International or National-Level *Athlete* in a *Registered Testing Pool* retires and then wishes to return to active participation in sport, the *Athlete* shall not compete in International Events or National Events until the *Athlete* has made himself or herself available for testing, by giving six months prior written notice to his or her International Federation and NADO Italia. WADA, in consultation with the relevant International Federation and NADO Italia, may grant an exemption to the six-month written notice rule where strict application of that rule would be manifestly unfair to an *Athlete*. This decision may be appealed under *Code* Article 13.
- 3.3** The required information shall include the following data for each day of the following quarter:
- a) personal details;
 - b) a complete mailing address and personal e-mail address where correspondence concerning the *Athlete* may be sent for formal notice purposes. Any notice or other document sent to the aforesaid address shall be considered as received by the *Athlete* within 7 (seven) working days of its mailing and immediately when notification of a sent registered e-mail is generated/obtained; it is understood that NADO Italia transmits the formal communications on the registered email given according to the Article 2.6;
 - c) specific confirmation that the *Athlete* understands that their Whereabouts Filing will be shared with other Anti-Doping Organizations that have authority to conduct Testing on them;
 - d) for each day during the following quarter, name and address of the place where the *Athlete* will be staying overnight (e.g. home, temporary accommodation, hotel, etc.);
 - e) for each day during the following quarter, the name and address of each location where the *Athlete* will train, work or conduct any other regular activity (e.g. school), as well as the usual time frames for such regular activities;
 - f) programme of sports events, including the name and address of each competition venue, where the *Athlete* plans to compete;
 - g) details of any *Athlete's* impairment which may affect the procedure to be followed for conducting a Sample Collection Session.
- 3.4** In addition to the foregoing information, the *Athlete* shall also be required to state a specific 60 (sixty) minute time slot between 05:00 am and 11:00 pm for each day of the quarter during which he/she will be available and accessible at the specified location to undergo Testing. It is up to the *Athlete* to ensure accessibility to their selected 60 (sixty) minutes location with no advance warning to the *Athlete* (e.g., the location shall be easily accessible by Sample Collection Personnel, by indicating a street number or other item identifying the location must be available, the *Athlete's* name must be shown on the door phone and/or notified to any concierge/reception desk services within the building/hotel, etc.). Under no circumstances shall the 60 (sixty) minute time slot limit the *Athlete's* obligation to make himself/herself available for Testing at any time and at any location.
- 3.5** It is the *Athlete's* explicit responsibility to ensure, including through updates entered in the

ADAMS system as necessary such appropriate Whereabouts Information is supplied as to enable NADO Italia to locate him/her for Testing in any given day during the quarter, including, but not limited to, the 60 (sixty) minute time slot specified for that day in his/her Whereabouts Information.

- 3.6** More specifically, the *Athlete* shall provide sufficient information to enable the DCO to find the location, to gain access to the location, and to find the *Athlete* at the location with no advance notice to the *Athlete*. A failure to do so may be pursued as a Filing Failure and/or (if the circumstances so warrant) as evasion of *Sample* collection under *ADSC* Article 2.3, and/or *Tampering* or *Attempted Tampering* with *Doping Control* under *ADSC* Article 2.5. In any event, the *Anti-Doping Organization* shall consider *Target Testing* of the *Athlete* (e.g.: *declarations such as “running in the Black Forest” are insufficient and are likely to result in a Filing Failure. Similarly, specifying a location that the DCO cannot access is likely to result in a Filing Failure.*
- 3.7** If the *Athlete* is tested during the 60-minute time slot, the *Athlete* must remain with the DCO until the *Sample* collection has been completed, even if this takes longer than the 60-minute time slot. A failure to do so shall be pursued as an apparent violation of *ADSC* Article 2.3 (refusal or failure to submit to *Sample* collection).
- 3.8** If the *Athlete* is not available for *Testing* at the beginning of the 60-minute time slot, but becomes available for *Testing* later on in the 60-minute time slot, the DCO should collect the *Sample* and should not process the attempt as an unsuccessful attempt to test, but should report the details of the delay in availability of the *Athlete*. Any pattern of behavior of this type should be investigated as a possible anti-doping rule violation of evading *Sample* collection under *ADSC* Article 2.3 or *ADSC* Article 2.5. It may also prompt *Target Testing* of the *Athlete*. If an *Athlete* is not available for *Testing* during their specified 60-minute time slot at the location specified for that time slot for that day, they will be liable for a Missed Test even if they are located later that day and a *Sample* is successfully collected from them.
- 3.9** Once the DCO has arrived at the location specified for the 60-minute time slot, if the *Athlete* cannot be located immediately, then the DCO should remain at that location for whatever time is left of the 60-minute time slot and during that remaining time they should do what is reasonable in the circumstances to try to locate the *Athlete*.
- 3.10** Where a change in circumstances means that the information in a Whereabouts Filing is no longer accurate or complete, the *Athlete* shall file, through *ADAMS*, an update so that the information on file is again accurate and complete. The *Athlete* must always update their Whereabouts Filing to reflect any change in any day in the quarter in question in particular: (a) in the time or location of the 60-minute time slot; and/or (b) in the place where they are staying overnight. The *Athlete* shall file the update as soon as possible after they become aware of the change in circumstances, and in any event prior to the 60-minute time slot specified in their filing for the relevant day. Under specific circumstances, however, any updates made by the *Athlete* immediately before the start of the time slot may be considered as possible violations of the *ADSC*. A failure to do so may be pursued as a Filing Failure and/or (if the circumstances so warrant) as evasion of *Sample* collection under *ADSC* Article 2.3, and/or *Tampering* or *Attempted Tampering* with *Doping Control* under *ADSC* Article 2.5. In any event, NADO Italia shall consider *Target Testing* of the *Athlete*.

3.11 An *Athlete* included in an RTP may delegate the task of filing of all or part of the Whereabouts Information (and/or any update thereof) to a third party including, but not limited to, a coach, a Team (for Team Sports as under Article 4), a manager or National Federation, provided that the third party accepts such task.

However, each *Athlete* shall remain personally responsible for filing his/her Whereabouts Information even if such task is delegated. It shall not be a defence to an allegation of Filing Failure and/or Missed Test under ADSC Article 2.4 that the *Athlete* delegated responsibility for filing his/her Whereabouts Information to a third party and that third party failed to file correct/current/complete Whereabouts Information.

ARTICLE 4 WHEREABOUTS INFORMATION IN TEAM SPORTS

4.1 An *Athlete* engaging in a Team Sport or other sports discipline where competitions and/or training are held on a collective basis may delegate the task of filing Whereabouts Information to his/her own team, entrusting the latter's personnel and staff with such task.

4.2 Indeed, in Team Sports *Athletes* are likely to carry out most of their activities (such as training, away matches, technical meetings) on a collective basis. As a result, most of the Whereabouts Information will be the same for all team *Athletes*. In addition, in the event that an *Athlete* does not take part in a scheduled collective activity (e.g. due to injury), then he/she is likely to engage in other activities under the supervision of his/her team (e.g. therapy with the team physician).

4.3 An *Athlete* who engages in such sports may also delegate Whereabouts Filing requirements to his/her team not only with respect to the Team Activities as referred to above, but also with regard to periods that do not fall under such Activities, subject to his/her Team's consent. In this event, the *Athlete* shall be required to provide his/her team with such information, which will supplement the information supplied with respect to Team Activities.

4.4 Under the circumstances as described above, the *Athlete* shall however remain personally responsible for filing his/her Whereabouts Information. It shall not be a defence to an allegation of Filing Failure and/or Missed Test under ADSC Article 2.4 that the *Athlete* delegated responsibility for filing his/her Whereabouts Information to a third party and that third party failed to file correct/ current/complete Whereabouts Information.

4.5 Notwithstanding the foregoing, if an attempt to test an *Athlete* during the 60 (sixty) minute time slot as identified within a period included in Team Activities fails due to the team's Filing Failure, then the team shall be liable to undergo disciplinary proceedings with subsequent infliction of the financial sanctions as under ADSC Article 15.

TITLE II SAMPLE COLLECTION'S PROCEDURE

ARTICLE 5 NOTIFICATION OF *ATHLETE*

5.1 Notification starts when the Sample Collection Authority initiates the notification of the selected Athlete and ends when he/she arrives at the Doping Control Station or when the *Athlete's* possible Failure to Comply has occurred.

The main activities are:

- a) appointment of Sample Collection Personnel, sufficient to ensure No Advance Notice Testing and continuous observation of *Athletes* notified of their selection to provide a *Sample*;
- b) locating the *Athlete* and confirming his/her identity;
- c) informing the *Athlete* that he/she has been selected for *Testing* and of his/her rights and responsibilities;
- d) continuously chaperoning the *Athlete* from the time of notification to the arrival at the designated Doping Control Station;
- e) documenting the notification, or notification attempt.

5.2 Requirements prior to notification of *Athletes*

5.2.1 No Advance Notice Testing shall be the method for *Sample* collection save in exceptional and justifiable circumstances. The *Athletes* shall be the first Person notified that they have been selected for *Sample* collection, except where prior contact with a third party is required as specified in ISTI Article 5.3.7. In order to ensure that *Testing* is conducted on a No Advance Notice Testing basis, the Testing Authority (and the Sample Collection Authority, if different) shall ensure that *Athlete* selection decisions are only disclosed in advance of *Testing* to those who strictly need to know in order for such *Testing* to be conducted. Any notification to a third party shall be conducted in a secure and confidential manner so that there is no risk that the *Athlete* will receive any advance notice of their selection for *Sample* collection. For In-Competition *Testing*, such notification shall occur at the end of the Competition in which the Athlete is competing.

5.2.2 The Sample Collection Authority shall appoint and authorize Sample Collection Personnel who (i) have been trained for their assigned responsibilities, (ii) do not have a conflict of interest in relation to *Sample* collection procedures, and (iii) are not minors. Sample Collection Personnel shall have official documentation, provided by the Sample Collection Authority, evidencing their authority to collect a *Sample* from the *Athlete*, such as an authorization letter from NADO Italia. DCOs shall also be required to hold valid personal identification papers bearing a photograph (e.g. identity card, driver's licence, passport) and the expiry date of the identification.

5.2.3 The *Athlete* selected for *Testing* shall be identified through his/her identity papers, federation membership card if bearing a photograph, or any piece of photo identification. If a photo identification is not available, the DCO/Chaperone will write on *Doping Control Form* 'No Document' in the 'Type of Identification' box. The DCO will then document how the *Athlete* was identified in the 'Comments' box of the DCF and the DCO Report Form. The DCO/Chaperone shall be required to document and record, using the Supplementary Report, any (i) circumstances where the *Athlete's* identity is confirmed using other methods, or (ii) failure to confirm the *Athlete's* identity. The Sample Collection Personnel shall document *Athlete* notification attempt(s) and outcome(s). The DCO and/or Chaperone shall establish the location of the selected *Athlete* and plan the approach and timing of notification, taking into consideration the specific circumstances of the sport/competition/training session.

5.2.4 Notification of testing shall be served personally on the *Athlete* selected for *Testing*, unless a

third party is required to be notified prior to notification of the *Athlete* in the following situations:

- a) where required by an *Athlete's* impairment (as provided for in Annex A - Modifications for *Athletes* with Impairments);
- b) where the *Athlete* is a Minor (as provided for in Annex B – Modifications for *Athletes* who are Minors);
- c) where an interpreter is required and available for the notification;
- d) where required to assist Sample Collection Personnel to identify the *Athlete(s)* to be tested and to notify such *Athlete(s)* that they are required to provide a *Sample*.

ARTICLE 6 REQUIREMENTS FOR NOTIFICATION OF *ATHLETES*

6.1 When initial contact is made, the Sample Collection Personnel shall ensure that the *Athlete* and/or a third party is informed:

- a) that the *Athlete* is required to undergo a *Sample* collection;
- b) of the authority under which the *Sample* collection is to be conducted;
- c) of the type and method of *Sample* collection and any conditions that need to be adhered to for the purposes of *Sample* collection;
- d) of the *Athlete's* rights, including the right to:
 - i. have a representative and, if necessary, an interpreter accompany him/her;
 - ii. ask for additional information about the *Sample* collection process;
 - iii. request a delay in reporting to the Doping Control Station for valid reasons;
 - iv. request modifications as provided for in Annex A – Modifications for *Athletes* with Impairments;
- e) of the *Athlete's* responsibilities, including the requirement to:
 - i. remain within direct observation of the Sample Collection Personnel at all times from the time of notification until the completion of the *Sample* collection procedure;
 - ii. produce identification in accordance with Article 5.2.3;
 - iii. comply with *Sample* collection procedures (and the *Athlete* should be informed of the possible consequences of Failure to Comply);
 - iv. report immediately for *Sample* collection, unless there are valid reasons for a delay, as determined in accordance with Article 6.3 here below;
- f) of the location of the Doping Control Station;
- g) that should the *Athlete* choose to consume food or fluids prior to providing a *Sample*, he/she does so at his/her own risk, while advising him/her that he/she should not hydrate excessively, having in mind the requirement to provide a *Sample* with a Suitable Specific Gravity for Analysis;
- h) that the urine *Sample* provided by the *Athlete* to the Sample Collection Personnel should be the first urine passed by the *Athlete* subsequent to notification (i.e., he/she should not pass urine in the shower or otherwise prior to providing a *Sample* to the Sample Collection Personnel).

6.2 After contact is made with the *Athlete*, the Sample Collection Personnel shall:

- a) keep the *Athlete* under observation at all times until the end of the *Sample* Collection

- Session;
- b) identify themselves to the *Athlete* using the documentation referred to in Article 5.2.2;
 - c) confirm the *Athlete's* identity as per the criteria established in Article 5.2.3. Any cases where the *Athlete's* identity cannot be confirmed it must be documented and reported to NADO Italia. NADO Italia shall decide whether it is appropriate to follow up in accordance with Annex A – Review of a Possible Failure to Comply of the Results Management Procedure_First Instance Proceedings and Appeals.

The Sample Collection Personnel shall then have the *Athlete* sign an appropriate form to acknowledge and accept the notification. If the *Athlete* refuses to sign that he/she has been notified, or evades the notification, the Sample Collection Personnel shall, if possible, inform the *Athlete* of the Consequences of refusing or failing to comply, and the Chaperone (if not the DCO) shall immediately report all relevant facts to the DCO, documenting such circumstance and informing NADO Italia. NADO Italia follows the steps prescribed in Annex A – Review of a Possible Failure to Comply of the Results Management Procedure_First Instance Proceedings and Appeals.

The DCO shall at any rate be required to carry on the *Sample* collection procedure.

6.3 The Sample Collection Personnel may at their discretion consider any reasonable third party request or any request by the *Athlete* for permission to delay reporting to the Doping Control Station following acknowledgment and acceptance of notification, and/or to leave the Doping Control Station temporarily after arrival, and may grant such permission if the *Athlete* can be continuously chaperoned and kept under direct observation during the delay. For example, delayed reporting to or temporary departure from the Doping Control Station may be permitted for the following activities:

- For In-Competition Testing:
 - a) Participation in a presentation ceremony;
 - b) Fulfilment of media commitments;
 - c) Competing in further competitions;
 - d) Performing a warm down;
 - e) Obtaining necessary medical treatment;
 - f) Locating a representative and/or interpreter;
 - g) Obtaining photo identification; or
 - h) Any other reasonable circumstances, as determined by DCO, taking into account any instructions of NADO Italia.
- For Out-of-Competition Testing:
 - a) Locating a representative;
 - b) Completing a training session;
 - c) Receiving necessary medical treatment;

- d) Obtaining photo identification; or
- e) Any other reasonable circumstances, as determined by DCO, considering any instructions of NADO Italia.

6.4 The Sample Collection Personnel shall reject a request for delay in reporting to the Doping Control Station if it is not possible for the *Athlete* to be continuously observed during such delay.

The Sample Collection Personnel shall use the Supplementary Report to document any reasons for the *Athlete's* delay in reporting to the Doping Control Station and/or reasons for leaving the Doping Control Station that may require further investigation by NADO Italia.

6.5 If the *Athlete* delays reporting to the Doping Control Station other than in accordance with Article 6.3 and/or any failure of the *Athlete* to remain under constant observation during chaperoning but the *Athlete* arrives at the Doping Control Station prior to the DCO's departure from the *Sample* collection location, the DCO shall report a possible Failure to Comply. If at all possible, the DCO shall proceed with collecting a *Sample* from the *Athlete*. NADO Italia shall investigate a possible Failure to Comply in accordance with Annex A – Review of a Possible Failure to Comply of the Results Management Procedure_First Instance Proceedings and Appeals.

6.6 If Sample Collection Personnel observe any other matter with potential to compromise the collection of the *Sample*, the circumstances shall be reported to and documented by the DCO. If deemed appropriate by the DCO, the DCO shall consider if it is appropriate to collect an additional *Sample* from the *Athlete*. NADO Italia shall investigate a possible Failure to Comply in accordance with Annex A – Review of a Possible Failure to Comply of the Results Management Procedure_First Instance Proceedings and Appeals.

ARTICLE 7 DCO AND BCO's DUTIES

As pursuant to the provisions laid down in the ISTI, Annex G and in the WADA Guidelines, the DCO/BCO are Sample Collection Personnel responsible for *Sample* collection-related services.

The DCO shall be responsible for:

- a) Organizing and training any additional Sample Collection Personnel;
- b) Contacting sports representatives, if necessary;
- c) Organizing equipment, including all forms and documents as necessary;
- d) Assessing and arranging facilities;
- e) Arranging and performing notification and chaperoning of *Athletes*;
- f) Ensuring that the *Athlete* is informed about his/her rights and responsibilities;
- g) Witnessing DCO entitlement to have a representative observe the witnessing DCO when the Minor Athlete is passing a urine *Sample*;
- h) Explaining the process of Urine *Sample* or Blood *Sample* collection to the *Athletes* and *Athletes'* representatives, as necessary;
- i) Overseeing *Sample* collection, including witnessing *Sample* provision;

- j) Coordinating Blood *Sample* collection, as necessary;
- k) Completing and verifying the relevant forms and documentation;
- l) Initiating and supervising the Chain of Custody of the testing phase, including organizing a delivery service, if necessary, ensuring that the waybill number is duly recorded if *Sample* transportation is arranged through a courier service;
- m) Dealing with the collection and disposal of waste resulting from *Sample* collection procedures.

ARTICLE 8 CHAPERONE'S DUTIES

As pursuant to the provisions laid down in the *WADA* Guidelines, a Chaperone shall be responsible for:

- a) Assisting the DCO in the conduct of anti-doping controls while strictly following his/her instructions;
- b) Informing the *Athlete* about his/her own identity by producing the official card and/or document vesting him/her with power of Chaperone;
- c) Personally informing the *Athlete* of the need for him/her to undergo Testing and his/her rights and duties, according to the DCO' instructions;
- d) Accompanying the *Athlete* while keeping direct visual contact from the time of notification to the *Athlete's* arrival at the Doping Control Station and thereafter, if so required by the DCO.

ARTICLE 9 DUTIES OF ANTI-DOPING DETECTIVE INSPECTORS (ADDIS)

Pursuant to the Framework Agreement executed on 9 February 2015 between CONI and the Carabinieri Department for Health Protection (i.e., the Italian anti-adulteration unit locally known as "NAS" or "CCTS"), NAS personnel accredited by NADO Italia as Anti-Doping Detective Inspectors ("ADDIS") shall take part to the anti-doping activities, in conjunction with FMSP's Doping Control Officers/Blood Control Officers.

During Testing as well as In-Competition Sample Collection Sessions, the ADDIS shall perform the following tasks in particular:

- a) To the extent as lying within their province and without prejudice to the duties and responsibilities of the DCO/BCO and Chaperones, they supervise the conduct of all of anti-doping phases in compliance with the ADSRs, such as:
 - Notification of Testing;
 - Sample Collection Session;
 - Documenting testing operations;
- b) When attending anti-doping procedures, they shall be required to show the card issued by NADO Italia and, if expressly requested by the *Athlete* or his/her representative, their personal identification card issued by the Carabinieri Corps;

- c) In conjunction with the DCO and Chaperone, they help identify *Athletes* who are unable to produce identity papers or a Federation membership card bearing a photo;
- d) They shall request the DCO to include the following in the anti-doping report:
 - Any requests made by the *Athlete*/third parties to
 - (i) interrupt the *Sample* collection phase due to kits that the *Athlete* claims to be non-compliant, or (ii) delay reporting to the Doping Control Station after notification has been received and accepted, or (iii) temporarily leave the Doping Control Station after arrival.
 - *Athlete*'s late arrival or early departure;
 - Any doubts arisen regarding the origin and genuineness of the *Sample* and the *Athlete*'s request to produce another *Sample*;
 - Any other matter that may compromise the legitimacy of the analyses or procedure compliance;
 - Any refusal by the *Athlete* to produce an additional *Sample* or sign the notification form.
- e) They shall sign the anti-doping control report together with all the other individuals attending the proceedings.

During Out-of-Competition Testing as well as Sample Collection Sessions, the ADDIs shall perform the following tasks:

- a) Help find the exact location of the *Athlete*(s) selected for Testing;
- b) To the extent as lying within their province and without prejudice to the duties and responsibilities of the DCO/BCO and Chaperones, they supervise the conduct of all of anti-doping phases in compliance with the ADSRs, such as:
 - Notification of Testing;
 - Sample Collection Session;
 - Documenting testing operations;
- c) When attending anti-doping procedures, they shall be required to show the card issued by NADO Italia and, if expressly requested by the *Athlete* or his/her representative, their personal identification card issued by the Carabinieri Corps;
- d) In conjunction with the DCO, they help identify *Athletes* who are unable to produce identity papers or a Federation membership card bearing a photo;
- e) They shall request the DCO to include the following in the anti-doping report:
 - Any requests made by the *Athlete*/third parties to

- (i) interrupt the *Sample* collection phase due to kits that the *Athlete* claims to be non-compliant, or (ii) delay reporting to the Doping Control Station after notification has been received and accepted, or (iii) temporarily leave the Doping Control Station after arrival.
 - *Athlete's* late arrival or early departure;
 - Any doubts arisen regarding the origin and genuineness of the *Sample* and the *Athlete's* request to produce another *Sample*;
 - Any other matter that may compromise the legitimacy of the analyses or procedure compliance;
 - Any refusal by the *Athlete* to produce an additional *Sample* or sign the notification form.
- f) They help identify the site where Testing is to be conducted;
 - g) They shall sign the anti-doping control report together with all the other individuals attending the proceedings.

TITLE III SAMPLE COLLECTION SESSION

ARTICLE 10 PREPARING FOR THE SAMPLE COLLECTION SESSION

- 10.1** For the purpose holding a Sample Collection Session, the following requirements need to be fulfilled beforehand:
- a) establishing an information collection system;
 - b) establishing criteria for who may be present during a Sample Collection Session;
 - c) ensuring that the Doping Control Station meets the minimum criteria prescribed in Article 7.3;
 - d) ensuring that the Sample Collection Equipment meets the minimum criteria prescribed in ISTI Article 6.3.4.
- 10.2** NADO Italia and the Sample Collection Authority shall establish a system for obtaining all the information necessary to ensure that the Sample Collection Session can be conducted effectively, including identifying specific requirements to meet the needs of *Athletes* with impairments (as provided in Annex A - Modifications for *Athletes* with Impairments) as well as the needs of *Athletes* who are *Minors* (as provided in Annex B - Modifications for *Athletes* who are *Minors*), consistent with applicable privacy provisions.
- 10.3** The Sample Collection Authority shall be required to use a Doping Control Station which, at a minimum, ensures the *Athlete's* privacy and confidentiality and is used solely as a Doping Control Station throughout the Session. Moreover, according to the WADA Guidelines applicable to In- Competition Testing, where possible, the Doping Control Station shall meet the following criteria:

- a) be accessible only to authorized personnel;
- b) be secure enough to store Sample Collection Equipment;
- c) be comprised of a waiting area with chairs and a separate area with a table and chairs for completion of paperwork. There should be adjacent toilet facilities large enough to allow *Sample* provision to be observed.
- d) include facilities to allow the *Athlete* to wash his/her hands;
- e) be large enough to accommodate the *Athletes* as well as authorized personnel;
- f) be suitably located in relation to the field of play or other location where *Athletes* will be notified.

With regard to Out-of-Competition Testing, when identifying the most suitable location the DCO/BCO shall take into account the demands and needs of the *Athlete* and/ third parties concerned with respect to privacy and dignity rights. However, no information concerning the *Athlete's* private life or unrelated third parties (e.g. family members) which is deemed as unnecessary, irrelevant or exceeding doping control purposes shall be collected.

Any non-compliance with the aforesaid requirements shall be documented by the DCO/BCO in the Supplementary Report form.

The Sample Collection Authority shall only use Sample Collection Equipment systems for urine and blood *Samples* which, at a minimum, complies with the requirements set out in ISTI Article 6.3.4.

10.4 In addition to the Sample Collection Personnel, the following people may be authorized by NADO Italia, to be present during the Sample Collection Session:

- a) representative and/or interpreter, if requested by the *Athlete*, except when the *Athlete* is passing a urine *Sample*;
- b) a Minor *Athlete's* entitlement (as provided for in Annex B – Modifications for *Athletes* who are Minors), and the witnessing DCO/Chaperone's entitlement to have a representative observe the witnessing DCO/Chaperone when the Minor *Athlete* is passing a urine *Sample*, but without the representative directly observing the passing of the *Sample* unless requested to do so by the Minor *Athlete*;
- c) a representative who accompanies an *Athlete* with impairment, if requested by the latter, pursuant to Annex A – Modifications for *Athletes* with Impairments;
- d) an Independent Observer, if sent by WADA under the *Independent Observer Programme*, or WADA auditor, where applicable;
- e) an authorized Person who is involved in the training of Sample Collection Personnel or auditing the Sample Collection Authority;
- f) a NADO Italia Observer if officially appointed for the event, including Anti-Doping Detective Inspectors (“ADDIs”) as referred to in *ADSC* Article 6.7.

The WADA observer/auditor and/or authorized Person shall not directly observe the passing of a urine *Sample*.

ARTICLE 11

CONDUCTING THE SAMPLE COLLECTION SESSION

- 11.1 The Sample Collection Session starts with defining the overall responsibility for the conduct of the Sample Collection Session and ends once the *Sample* has been collected and secured and the Sample Collection Session documentation is complete.
- 11.2 The main activities are:
- a) preparing for collecting the *Sample*;
 - b) collecting and taking all steps to secure the *Sample*;
 - c) documenting the *Sample* collection.
- 11.3 The Sample Collection Authority shall be responsible for the overall conduct of the Sample Collection Session, with specific responsibilities being either delegated to or lying with the DCO/BCO.
- 11.4 The DCO shall ensure that the *Athlete* has been informed of his/her rights and responsibilities.
- 11.5 The DCO shall advise the *Athlete* not to hydrate excessively, having in mind the requirement to provide a *Sample* with a Suitable Specific Gravity for Analysis.
- 11.6 NADO Italia prohibits the provision of alcohol or its consumption within the Doping Control Station.
- 11.7 The *Athlete* shall only leave the Doping Control Station under continuous observation by the DCO or Chaperone and with the approval of the DCO. The DCO shall consider any reasonable request by the *Athlete* to leave the Doping Control Station, as specified in Article 6.3, until the *Athlete* is able to provide a *Sample*.
- 11.8 If the DCO gives approval for the *Athlete* to leave the Doping Control Station, the DCO shall agree with the *Athlete* on the following conditions of leave:
- a) the purpose of the *Athlete* leaving the Doping Control Station;
 - b) establish and agree with the *Athlete* the time of return (or return upon completion of an agreed activity).
 - c) ensure that the *Athlete* remains under continuous observation throughout;
 - d) restrict the *Athlete* from passing urine until he/she returns to the Doping Control Station.
 - e) the DCO shall be required to document the actual time of the *Athlete's* departure and return.
- 11.9 The DCO shall collect the *Sample* from the *Athlete* according to the following protocol(s) for the specified type of *Sample* collection:
- a) Annex C: Collection of Urine *Samples*;

- b) Annex D: Collection of Blood *Samples*;
- c) Annex I: Collection, Storage and Transportation of Blood *Athlete* Biological Passport *Samples*.

11.10 Any behaviour by the *Athlete* and/or Persons associated with the *Athlete* or anomalies with potential to compromise the *Sample* collection shall be recorded in detail by the DCO using the Supplementary Report form. If appropriate, NADO Italia shall institute the procedures under Annex A – Review of a possible Failure to Comply, “Results Managements Procedure_First Instance Proceeding and Appeals”.

11.11 If there are doubts as to the origin or authenticity of the *Sample*, the *Athlete* shall be asked to provide an additional *Sample*. If the *Athlete* refuses to provide an additional *Sample*, the DCO shall document in detail the circumstances around the refusal using the Supplementary Report form, and NADO Italia shall institute the procedures under Annex A – Review of a possible Failure to Comply, “Results Managements Procedure_First Instance Proceeding and Appeals”.

11.12 The DCO shall provide the *Athlete* with the opportunity to document any concerns he/she may have about how the Sample Collection Session was conducted.

11.13 In conducting the Sample Collection Session, the following information shall be recorded in the relevant report:

- a) date, time of notification, name and signature of notifying DCO/Chaperone;
- b) arrival time of the *Athlete* at the Doping Control Station and any temporary departures and returns;
- c) date and time of sealing of each *Sample* collected and date and time of completion of entire *Sample* collection process (i.e., the time when the *Athlete* signs the declaration at the bottom of the Doping Control form);
- d) the name of the *Athlete*;
- e) the date of birth of the *Athlete*;
- f) the gender of the *Athlete*;
- g) means by which the *Athlete*'s identity is validated (e.g., passport, driver's license or *Athlete* accreditation) including by a third party (who is so identified)
- h) the *Athlete*'s home address, email address and telephone number;
- i) the *Athlete*'s sport and discipline (in accordance with the TDSSA);
- j) the name of the *Athlete*'s coach and doctor (if applicable);
- k) the *Sample* code number and reference to the equipment manufacturer;
- l) the type of the *Sample* (urine, blood, etc.);
- m) the type of Testing (In-Competition or Out-of-Competition);
- n) the name and signature of the witnessing DCO;
- o) the name and signature of the BCO (where applicable);
- p) partial *Sample* information, as per Article E.4.4, Annex E;
- q) required Laboratory information on the *Sample* (i.e., for a urine *Sample*, its volume and specific gravity measurement);
- r) medications and supplements taken within the previous seven (7) days and (where the *Sample* collected is a blood *Sample*) blood transfusions within the previous three (3) months, as declared by the *Athlete*;

- s) for an *Athlete* Biological Passport blood *Sample*, the DCO/BCO shall record the information as outlined in Annex I - Collection, Storage and Transport of Blood *Athlete* Biological Passport *Samples*;
- t) any irregularities in procedures, for example, if advance notice was provided;
- u) *Athlete* comments or concerns regarding the conduct of the Sample Collection Session, as declared by the *Athlete*;
- v) *Athlete* acknowledgment of the Processing of *Sample* collection data and description of such Processing in accordance with the International Standard for the Protection of Privacy and Personal Information, with the GDPR, EU 2016/679 and pursuant to Legislative Decree n. 196/2003 as amended by Legislative Decree n. 101/2018;
- w) *Athlete* consent or otherwise for the use of the *Sample(s)* for research purposes;
- x) the name and signature of the *Athlete's* representative (if applicable), as per Article 8.11;
- y) the name and signature of the *Athlete*;
- z) the name and signature of the DCO;
- aa) the name of the Testing Authority;
- bb) the name of the Sample Collection Authority;
- cc) the name of the Results Management Authority; and
- dd) the name of the Doping Control Coordinator (if applicable).

11.14 At the conclusion of the Sample Collection Session, the *Athlete* and DCO shall sign appropriate documentation to indicate their satisfaction that the documentation accurately reflects the details of the *Athlete's* Sample Collection Session, including any concerns expressed by the *Athlete*. The *Athlete's* representative, if present and who witnessed the proceedings, should sign the documentation. Other persons present who had a formal role during the *Athlete's* Sample Collection Session may sign the documentation as a witness of the proceedings.

11.15 The DCO shall provide the *Athlete* with a copy of the records of the Sample Collection Session that have been signed by the *Athlete*.

11.16 The *Doping Control Form*, duly completed and signed in all of its sections by the DCO, shall be prepared in 3 copies (NADO Italia, *Athlete* and WADA-accredited laboratory) and delivered as follows:

- a) NADO Italia: The DCO shall arrange for the reports of all the *Athletes* to be placed in an envelope bearing the details of the NSF/ASD/SPE concerned (or ADO/Organization concerned), event, venue and date. The envelope shall be promptly sent to NADO Italia. The *Athlete's* notification, the Supplementary Report (if any) and other documentation shall be placed solely in the parcel to be delivered to NADO Italia.
- b) *Athlete*: Upon completion of the Sample Collection Session, the DCO shall hand over to the *Athlete* his/her copy of the session report.
- c) Laboratory: The copy(ies) intended for the WADA-accredited laboratory shall not contain any information identifying the *Athlete* and shall be placed by the DCO in a carrying case containing the collected *Samples*, while the Chain of Custody shall be kept out of the case in order that it may be updated during the different stages.

**TITLE IV SECURITY, POST-TEST ADMINISTRATION PROCEDURE,
TRANSPORT AND OWNERSHIP OF SAMPLES**

ARTICLE 12 REQUIREMENTS

- 12.1 Post-test administration begins when the *Athlete* has left the Doping Control Station after providing his/her *Sample(s)*, and ends with preparation of all of the collected *Samples* and *Sample* collection documentation for transport.
- 12.2 The Sample Collection Authority shall, through the DCO, ensure that all sealed *Samples* are stored in a manner that protects their integrity, identity and security prior to transport from the Doping Control Station. In the event that the *Samples* are stored, the location where *Samples* are stored, who has custody of the *Samples* and/or who is permitted access to the *Samples* shall also be documented.
- 12.3 The Sample Collection Authority shall develop a system for recording the Chain of Custody of the *Samples* and *Sample* collection documentation to ensure that the documentation for each *Sample* is completed and securely handled. This shall include confirming that both the *Samples* and *Sample* collection documentation have arrived at their intended destinations. The Laboratory shall report any irregularities to NADO Italia on the condition of *Samples* upon arrival in line with the ISL.
- 12.4 Insofar as necessary, NADO Italia, through the DCO, shall ensure that instructions for the type of analysis to be conducted are provided to the WADA-accredited laboratory or other WADA-approved laboratory. In addition, NADO Italia, shall, through the DCO, provide the information as under Article 8.10, paragraphs c), f), i), k), l), m), q), r), w), aa), bb), cc) for result reporting and statistical purposes. To this end, the copy of the form designed for the laboratory shall be used.

ARTICLE 13 TRANSPORT OF SAMPLES AND DOCUMENTATION

- 13.1 Transport starts when the sealed *Samples* and related Sample Collection Session documentation leave the Doping Control Station and ends with the confirmed receipt of the *Samples* and related documentation at their intended destinations.
- 13.2 The Sample Collection Authority shall authorize a transport system that ensures *Samples* and documentation are transported in a manner that protects their integrity, identity and security.
- 13.3 *Samples* shall always be transported to the Laboratory that will be analyzing the *Samples* using the Sample Collection Authority's authorized transport method, as soon as possible after the completion of the Sample Collection Session. *Samples* shall be transported in a manner which minimizes the potential for *Sample* degradation due to factors such as time delays and extreme temperature variations.
- 13.4 The documentation identifying the *Athlete* shall not be attached to the *Samples* or documentation sent to the laboratory.

- 13.5 If the *Samples*, complete with the relevant documentation or Sample Collection Session report, are not acknowledged to have been received at their respective intended destinations, or if a Sample's integrity or identity may have been compromised during transport, then the Sample Collection Authority shall check the Chain of Custody, and NADO Italia shall consider whether the *Samples* should be voided.
- 13.6 Documentation related to a Sample Collection Session and/or an anti-doping rule violation shall be stored for the period and other requirements specified in the International Standard for the Protection of Privacy and Personal Information, and according to GDPR, EU 2016/679 and pursuant to Legislative Decree no. 196/2003 as amended by Legislative Decree no. 101/2018.

ARTICLE 14 OWNERSHIP OF SAMPLES

- 14.1 *Samples* collected from an *Athlete* are owned by NADO Italia for the Sample Collection Session in question.
- 14.2 NADO Italia, upon request, may transfer such ownership to the Anti-Doping Organization responsible for *Results Management*, if different from NADO Italia or to another Anti-Doping Organization upon request.
- 14.3 WADA may assume Testing Authority in certain circumstances in accordance with the Code and the ISL.
- 14.4 Where NADO Italia is not the Passport Custodian, but initiated and directed the Sample collection, it maintains the responsibility for additional Analytical Testing of the Sample. This includes the performance of further Confirmation Procedure(s) upon requests generated automatically by the Adaptive Model of the *Athlete* Biological Passport in *ADAMS* (e.g., GC/C/IRMS triggered by elevated T/E) or a request by the APMU (e.g., GC/C/IRMS requested due to abnormal secondary Markers of the urinary "longitudinal steroid profile" or ESA analysis tests due to suspicious haematological Marker values).

ANNEX A – MODIFICATIONS FOR *ATHLETES* WITH IMPAIRMENTS

A.1. Objective

To ensure that the particular needs of *Athletes* with impairments are considered in relation to the provision of a Sample, where possible, without compromising the integrity of the Sample Collection Session.

A.2. Scope

Determining whether modifications are necessary starts with identification of situations where Sample collection involves *Athletes* with impairments and ends with modifications to Sample collection procedures and equipment where necessary and where possible.

A.3. Responsibility

A.3.1 NADO Italia or the Sample Collection Authority (as applicable) has responsibility for ensuring, when possible, that the DCO has any information and Sample Collection Equipment necessary to conduct a Sample Collection Session with an *Athlete* with an impairment, including details of such impairment that may affect the procedure to be followed in conducting a Sample Collection Session.

A.3.2 The DCO has responsibility for Sample collection.

A.4. Requirements

A.4.1 All aspects of notification and Sample collection for *Athletes* with impairments shall be carried out in accordance with the standard notification and Sample collection procedures unless modifications are necessary due to the *Athlete's* impairment. NADO Italia in the case of an *Athlete* with an intellectual impairment, shall decide whether to obtain consent to Testing from their representative and inform the Sample Collection Authority and Sample Collection Personnel.

A.4.2 In planning or arranging Sample collection, the Sample Collection Authority and DCO shall consider whether there will be any Sample collection for *Athletes* with impairments that may require modifications to the standard procedures for notification or Sample collection, including Sample Collection Equipment and Doping Control Station.

A.4.3 The Sample Collection Authority and DCO shall have the authority to make modifications as the situation requires when possible and as long as such modifications will not compromise the identity, security or integrity of the Sample. The DCO shall consult the *Athlete* in order to determine what modifications may be necessary for the *Athlete's* impairment. All such modifications shall be documented.

A.4.4 An *Athlete* with an intellectual, physical or sensorial impairment may be assisted by the *Athlete's* representative or Sample Collection Personnel during the Sample Collection Session where authorized by the *Athlete* and agreed to by the DCO.

- A.4.5 The DCO may decide that alternative Sample Collection Equipment or an alternative Doping Control Station will be used when required to enable the *Athlete* to provide the Sample, as long as the Sample's identity, security and integrity will not be affected.
- A.4.6 *Athletes* who are using urine collection or drainage systems are required to eliminate existing urine from such systems before providing a urine Sample for analysis. Where possible, the existing urine collection or drainage system should be replaced with a new, unused catheter or drainage system prior to collection of the Sample. The catheter or drainage system is not a required part of Sample Collection Equipment to be provided by the Sample Collection Authority; instead it is the responsibility of the *Athlete* to have the necessary equipment available for this purpose.
- A.4.7 For *Athletes* with visual or intellectual impairments, the DCO and/or *Athlete* may determine if they shall have a representative present during the Sample Collection Session. During the Sample Collection Session, a representative of the *Athlete* and/or a representative of the DCO may observe the witnessing DCO/Chaperone while the *Athlete* is passing the urine Sample. This representative or these representatives may not directly observe the passing of the urine Sample, unless requested to do so by the *Athlete*.
- A.4.8 The DCO shall record modifications made to the standard Sample collection procedures for *Athletes* with impairments, including any applicable modifications specified in the above actions.

ANNEX B – MODIFICATIONS FOR *ATHLETES* WHO ARE MINORS

B.1. Objective

To ensure that the particular needs of *Athletes* who are Minors are met in relation to the provision of a Sample, where possible, without compromising the integrity of the Sample Collection Session.

B.2. Scope

Determining whether modifications are necessary starts with identification of situations where Sample collection involves *Athletes* who are Minors and ends with modifications to Sample collection procedures where necessary and where possible.

B.3. Responsibility

B.3.1 NADO Italia has responsibility for ensuring, when possible, that the DCO has any information necessary to conduct a Sample Collection Session with an *Athlete* who is a Minor. This includes confirming wherever necessary that the necessary parental consent for Testing any participating *Athlete* who is a Minor.

B.3.2 The DCO has responsibility for Sample collection.

B.4. Requirements

B.4.1 All aspects of notification and Sample collection for *Athletes* who are Minors shall be carried out in accordance with the standard notification and Sample collection procedures unless modifications are necessary due to the *Athlete* being a Minor.

B.4.2 In planning or arranging Sample collection, the Sample Collection Authority and DCO shall consider whether there will be any Sample collection for *Athletes* who are Minors that may require modifications to the standard procedures for notification or Sample collection.

B.4.3 The Sample Collection Authority and the DCO shall have the authority to make modifications as the situation requires when possible and as long as such modifications will not compromise the identity, security or integrity of the Sample. All such modifications shall be documented.

B.4.4 *Athletes* who are Minors should be notified in the presence of an *Athlete* representative (who is not a Minor) in addition to the DCO/Chaperone, and may choose to be accompanied by a representative throughout the entire Sample Collection Session. Even if the Minor declines a representative, the Sample Collection Authority or DCO, as applicable, shall consider whether another third party ought to be present during notification of the *Athlete*.

B.4.5 Should an *Athlete* who is a Minor decline to have a representative present during the collection of a Sample, this shall be clearly documented by the DCO. This does not invalidate the Test, but shall be recorded.

B.4.6 The DCO shall determine who may be present during the collection of a Sample from an

Athlete who is a Minor, in addition to a representative of the DCO/Chaperone who shall be present. A representative of the Minor may be present during Sample provision (including observing the DCO when the Minor is passing the urine Sample, but not directly observing the passing of the urine Sample unless requested to do so by the Minor). The DCO's/Chaperone's representative shall only observe the DCO/Chaperone and shall not directly observe the passing of the Sample.

B.4.7 The preferred venue for all Out-of-Competition Testing of a Minor is a location where the presence of an *Athlete* representative (who is not a Minor) is most likely to be available for the duration of the Sample Collection Session, e.g., a training venue.

B.4.8 NADO Italia or Sample Collection Authority (as applicable) shall consider the appropriate course of action when no *Athlete* representative (who is not a Minor) is present at the Testing of an *Athlete* who is a Minor (for example by ensuring that more than one Sample Collection Personnel is present during a Sample Collection Session of such Minor *Athlete*) and shall accommodate the Minor in locating a representative if requested to do so by the Minor.

ANNEX C - COLLECTION OF URINE SAMPLES

C.1. Objective

To collect an *Athlete's* urine *Sample* in a manner that ensures:

- a) Consistency with relevant principles of internationally recognized standard precautions in healthcare settings so that the health and safety of the *Athlete* and Sample Collection Personnel are not compromised;
- b) The *Sample* meets the Suitable Specific Gravity for Analysis and the Suitable Volume of Urine for Analysis. Failure of a *Sample* to meet these requirements in no way invalidates the suitability of the *Sample* for analysis. The determination of a *Sample's* suitability for analysis is the decision of the relevant Laboratory, in consultation with the Testing Authority for the Sample Collection Session in question;
- c) the *Sample* has not been manipulated, substituted, contaminated or otherwise tampered with in any way;
- d) the *Sample* is clearly and accurately identified; and
- e) the *Sample* is securely sealed in a Tamper Evident kit.

C.2. Scope

The collection of a urine *Sample* begins with ensuring the *Athlete* is informed of the *Sample* collection requirements and ends with discarding any residual urine remaining at the end of the *Athlete's* Sample Collection Session.

C.3. Responsibility

C.3.1 The DCO has the responsibility for ensuring that each *Sample* is properly collected, identified and sealed.

C.3.2 The DCO/Chaperone has the responsibility for directly witnessing the passing of the urine *Sample*.

C.4. Requirements

C.4.1 The DCO shall ensure that the *Athlete* is informed of the requirements of the Sample Collection Session, including any modifications as provided for in Annex A – Modifications for *Athletes* with Impairments.

C.4.2 The DCO shall ensure that the *Athlete* is offered a choice of *Sample* collection vessels for collecting the *Sample*. If the nature of an *Athlete's* impairment requires that they must use additional or other equipment as provided for in Annex A - Modifications for *Athletes* with Impairments, the DCO shall inspect that equipment to ensure that it will not affect

the identity or integrity of the *Sample*.

- C.4.3 When the *Athlete* selects a collection vessel, and for selection of all other Sample Collection Equipment that directly holds the urine *Sample*, the DCO will instruct the *Athlete* to check that all seals on the selected equipment are intact and the equipment has not been tampered with. If the *Athlete* is not satisfied with the selected equipment, they may select another. If the *Athlete* is not satisfied with any of the equipment available for selection, this shall be recorded by the DCO. If the DCO does not agree with the *Athlete* that all of the equipment available for the selection is unsatisfactory, the DCO shall instruct the *Athlete* to proceed with the Sample Collection Session. If the DCO agrees with the *Athlete* that all of the equipment available for the selection is unsatisfactory, the DCO shall terminate the Sample Collection Session and this shall be recorded by the DCO.
- C.4.4 The *Athlete* shall retain control of the collection vessel and any *Sample* provided until the *Sample* (or partial *Sample*) is sealed, unless assistance is required by reason of an *Athlete's* impairment as provided for in Annex A - Modifications for *Athletes* with Impairments. Additional assistance may be provided in exceptional circumstances to any *Athlete* by the *Athlete's* representative or Sample Collection Personnel during the Sample Collection Session where authorized by the *Athlete* and agreed to by the DCO.
- C.4.5 The DCO/Chaperone who witnesses the passing of the *Sample* shall be of the same gender as the *Athlete* providing the *Sample* and where applicable, based on the gender of the Event the *Athlete* competed in.
- C.4.6 The DCO/Chaperone shall, where practicable, ensure the *Athlete* thoroughly washes their hands with water only prior to the provision of the *Sample* or wears suitable (e.g., disposable) gloves during provision of the *Sample*.
- C.4.7 The DCO/Chaperone and *Athlete* shall proceed to an area of privacy to collect a *Sample*.
- C.4.8 The DCO/Chaperone shall ensure an unobstructed view of the *Sample* leaving the *Athlete's* body and shall continue to observe the *Sample* after provision until the *Sample* is securely sealed. In order to ensure a clear and unobstructed view of the passing of the *Sample*, the DCO/Chaperone shall instruct the *Athlete* to remove or adjust any clothing which restricts the DCO's/Chaperone's clear view of *Sample* provision.
- C.4.9 The DCO/Chaperone shall ensure that urine passed by the *Athlete* is collected in the collection vessel to its maximum capacity and thereafter the *Athlete* is encouraged to fully empty their bladder into the toilet. The DCO shall verify, in full view of the *Athlete*, that the Suitable Volume of Urine for Analysis has been provided.
- C.4.10 Where the volume of urine provided by the *Athlete* is insufficient, the DCO shall follow the partial *Sample* collection procedure set out in Annex E - Urine *Samples* - Insufficient Volume.
- C.4.11 Once the volume of urine provided by the *Athlete* is sufficient, the DCO shall instruct the *Athlete* to select a *Sample* collection kit containing A and B bottles or containers in

accordance with Annex C.4.3.

- C.4.12 Once a *Sample* collection kit has been selected, the DCO and the *Athlete* shall check that all *Sample* code numbers match and that this code number is recorded accurately by the DCO on the Doping Control form. If the *Athlete* or DCO finds that the numbers are not the same, the DCO shall instruct the *Athlete* to choose another kit in accordance with Annex C.4.3. The DCO shall record the matter.
- C.4.13 The *Athlete* shall pour the minimum Suitable Volume of Urine for Analysis into the B bottle or container (to a minimum of 30 mL), and then pour the remainder of the urine into the A bottle or container (to a minimum of 60 mL). The Suitable Volume of Urine for Analysis shall be viewed as an absolute minimum. If more than the minimum Suitable Volume of Urine for Analysis has been provided, the DCO shall ensure that the *Athlete* fills the A bottle or container to capacity as per the recommendation of the equipment manufacturer. Should there still be urine remaining, the DCO shall ensure that the *Athlete* fills the B bottle or container to capacity as per the recommendation of the equipment manufacturer. The DCO shall instruct the *Athlete* to ensure that a small amount of urine is left in the collection vessel, explaining that this is to enable the DCO to test the residual urine in accordance with Annex C.4.15.
- C.4.14 The *Athlete* shall then seal the A and B bottles or containers as directed by the DCO. The DCO shall check, in full view of the *Athlete*, that the bottles or containers have been properly sealed.
- C.4.15 The DCO shall test the residual urine in the collection vessel to determine if the *Sample* has a Suitable Specific Gravity for Analysis. If the DCO's field reading indicates that the *Sample* does not have a Suitable Specific Gravity for Analysis, then the DCO shall follow Annex F - Urine *Samples* that do not meet the requirement for Suitable Specific Gravity for Analysis.
- C.4.16 Urine should only be discarded when both the A and B bottles or containers have been sealed and the residual urine has been tested in accordance with Annex C.4.15.
- C.4.17 The *Athlete* shall be given the option of witnessing the discarding of any residual urine that will not be sent for analysis.

ANNEX D – COLLECTION OF BLOOD SAMPLES

D.1. Objective

To collect an *Athlete's* blood *Sample* in a manner that ensures:

- a) Consistency with relevant principles of internationally recognized standard precautions in healthcare settings, and is collected by a suitably qualified Person, so that the health and safety of the *Athlete* and Sample Collection Personnel are not compromised;
- b) The *Sample* is of a quality and quantity that meets the relevant analytical guidelines;
- c) The *Sample* has not been manipulated, substituted, contaminated or otherwise tampered with in any way;
- d) The *Sample* is clearly and accurately identified; and
- e) The *Sample* is securely sealed in a Tamper Evident kit.

D.2. Scope

The collection of a blood *Sample* begins with ensuring the *Athlete* is informed of the *Sample* collection requirements and ends with properly storing the *Sample* prior to transport to the Laboratory that will be analyzing the *Sample*.

D.3. Responsibility

D.3.1 The DCO has the responsibility for ensuring that:

- a) Each *Sample* is properly collected, identified and sealed; and
- b) All *Samples* have been properly stored and dispatched in accordance with the relevant analytical guidelines.

D.3.2 The BCO has the responsibility for collecting the blood *Sample*, answering related questions during the provision of the *Sample*, and proper disposal of used blood sampling equipment not required to complete the Sample Collection Session.

D.4. Requirements

D.4.1 Procedures involving blood shall be consistent with the local standards and regulatory requirements regarding precautions in healthcare settings where those standards and requirements exceed the requirements set out below.

D.4.2 Blood Sample Collection Equipment shall consist of:

- a) Collection tube(s) which meet the requirements of Article 6.3.4; and/or

- b) A and B bottles/containers for the secure transportation of collection tubes; and/or
 - c) Unique labels for collection tubes with a *Sample* code number; and/or
 - d) Such other types of equipment to be used in connection with the collection of blood as set out in Article 6.3.4 and WADA's *Sample* Collection Guidelines.
- D.4.3 The DCO shall ensure that the *Athlete* is properly notified of the requirements of the *Sample* collection, including any modifications as provided for in Annex A - Modifications for *Athletes* with Impairments.
- D.4.4 The DCO/Chaperone and *Athlete* shall proceed to the area where the *Sample* will be provided.
- D.4.5 The DCO/BCO shall ensure the *Athlete* is offered comfortable conditions and shall instruct the *Athlete* to remain in a normal seated position with feet on the floor for at least 10 minutes prior to providing a *Sample*.
- D.4.6 The DCO/BCO shall instruct the *Athlete* to select the *Sample* collection kit(s) required for collecting the *Sample* and to check that the selected equipment has not been tampered with and the seals are intact. If the *Athlete* is not satisfied with a selected kit, they may select another. If the *Athlete* is not satisfied with any kits and no others are available, this shall be recorded by the DCO. If the DCO does not agree with the *Athlete* that all of the available kits are unsatisfactory, the DCO shall instruct the *Athlete* to proceed with the Sample Collection Session. If the DCO agrees with the *Athlete* that all available kits are unsatisfactory, the DCO shall terminate the Sample Collection Session and this shall be recorded by the DCO.
- D.4.7 When a *Sample* collection kit has been selected, the DCO and the *Athlete* shall check that all *Sample* code numbers match and that this *Sample* code number is recorded accurately by the DCO on the Doping Control form. If the *Athlete* or DCO finds that the numbers are not the same, the DCO shall instruct the *Athlete* to choose another kit. The DCO shall record the matter.
- D.4.8 The BCO shall assess the most suitable location for venipuncture that is unlikely to adversely affect the *Athlete* or their performance. This should be the non-dominant arm, unless the BCO assesses the other arm to be more suitable. The BCO shall clean the skin with a sterile disinfectant wipe or swab and, if required apply a tourniquet. The BCO shall take the blood *Sample* from a superficial vein into the tube. The tourniquet, if applied, shall be immediately removed after the venipuncture has been made.
- D.4.9 The amount of blood removed shall be adequate to satisfy the relevant analytical requirements for the *Sample* analysis to be performed, as set out in WADA's *Sample* Collection Guidelines.
- D.4.10 If the amount of blood that can be removed from the *Athlete* at the first attempt is insufficient, the BCO shall repeat the procedure up to a maximum of three (3) attempts in total. Should all three (3) attempts fail to produce a sufficient amount of blood, then the BCO shall inform the DCO. The DCO shall terminate the blood *Sample* collection and record the reasons for

terminating.

- D.4.11 The BCO shall apply a dressing to the puncture site(s).
- D.4.12 The BCO shall dispose of used blood sampling equipment not required to complete the Sample Collection Session in accordance with the required local standards for handling blood.
- D.4.13 If the *Sample* requires further on-site processing, such as centrifugation or separation of serum (for example, in the case of a *Sample* intended for use in connection with the *Athlete* Biological Passport program), after the blood flow into the tube ceases, the BCO shall remove the tube from the holder and homogenize the blood in the tube manually by inverting the tube gently at least three (3) times). The *Athlete* shall remain in the blood collection area and observe their *Sample* until it is sealed in a Tamper Evident kit.
- D.4.14 The *Athlete* shall seal their *Sample* into a Tamper Evident kit as directed by the DCO. In full view of the *Athlete*, the DCO shall check that the sealing is satisfactory. The *Athlete* and the BCO/DCO shall sign the Doping Control form.
- D.4.15 The sealed *Sample* shall be stored in a manner that protects its integrity, identity and security prior to transport from the Doping Control Station to the Laboratory that will be analyzing the *Sample*.
- D.4.16 Blood *Samples* shall be transported in accordance with Article 9 and WADA's *Sample* Collection Guidelines. The transport procedure is the responsibility of the DCO. Blood *Samples* shall be transported in a device that maintains the integrity of *Samples* over time, in a cool and constant environment, measured by a temperature data logger notwithstanding changes in external temperature. The transport device shall be transported by secure means using a method authorized by NADO Italia or Sample Collection Authority.

ANNEX E – URINE SAMPLES – INSUFFICIENT VOLUME

E.1. Objective

To ensure that where a Suitable Volume of Urine for Analysis is not provided, appropriate procedures are followed.

E.2. Scope

The procedure begins with informing the *Athlete* that the *Sample* that they have provided is not of Suitable Volume of Urine for Analysis and ends with the *Athlete's* provision of a *Sample* of sufficient volume.

E.3. Responsibility

The DCO has the responsibility for declaring the *Sample* volume insufficient and for collecting the additional *Sample(s)* to obtain a combined *Sample* of sufficient volume.

E.4. Requirements

E.4.1 If the *Sample* collected is of insufficient volume, the DCO shall inform the *Athlete* that a further *Sample* shall be collected to meet the Suitable Volume of Urine for Analysis requirements.

E.4.2 The DCO shall instruct the *Athlete* to select partial Sample Collection Equipment in accordance with Annex C.4.3.

E.4.3 The DCO shall then instruct the *Athlete* to open the relevant equipment, pour the insufficient *Sample* into the new container (unless the Sample Collection Authority's procedures permit retention of the insufficient *Sample* in the original collection vessel) and seal it using a partial *Sample* sealing system, as directed by the DCO. The DCO shall check, in full view of the *Athlete*, that the container (or original collection vessel, if applicable) has been properly sealed.

E.4.4 The DCO shall record the partial *Sample* number and the volume of the insufficient *Sample* on the Doping Control form and confirm its accuracy with the *Athlete*. The DCO shall retain control of the sealed partial *Sample*.

E.4.5 While waiting to provide an additional *Sample*, the *Athlete* shall remain under continuous observation and be given the opportunity to hydrate in accordance with Article 8.3.

E.4.6 When the *Athlete* is able to provide an additional *Sample*, the procedures for collection of the *Sample* shall be repeated as prescribed in Annex C - Collection of Urine *Samples*, until a sufficient volume of urine will be provided by combining the initial and additional *Sample(s)*.

E.4.7 Following each *Sample* provided, the DCO and *Athlete* shall check the integrity of the seal(s) on the container(s) containing the previously provided partial *Sample(s)*. Any irregularity with the integrity of the seal(s) will be recorded by the DCO and investigated according to Annex A – Review of a Possible Failure to Comply of the “Results Management Procedure_First Instance Proceedings and Appeals”. The DCO may request that an additional *Sample* is

collected from the *Athlete*. A refusal to provide a further *Sample* if requested, where the minimum requirements for *Sample* collection volume are not met, shall be recorded by the DCO and dealt with as a potential Failure to Comply in accordance with the International Standard for Results Management.

- E.4.8 The DCO shall then direct the *Athlete* to break the seal(s) and combine the *Samples*, ensuring that additional *Samples* are added in the order they were collected to the original partial *Sample* until, as a minimum, the requirement for Suitable Volume of Urine for Analysis is met.
- E.4.9 The DCO and the *Athlete* shall then continue with Annex C.4.12 or Annex C.4.14 as appropriate.
- E.4.10 The DCO shall check the residual urine in accordance with Annex C.4.15 to ensure that it meets the requirement for Suitable Specific Gravity for Analysis in accordance with Annex F.
- E.4.11 Urine should only be discarded when both the A and B bottles or containers have been filled to capacity in accordance with Annex C.4.14 and the residual urine has been checked in accordance with Annex C.4.15. The Suitable Volume of Urine for Analysis shall be viewed as an absolute minimum.

ANNEX F – URINE SAMPLES THAT DO NOT MEET THE REQUIREMENT FOR SUITABLE SPECIFIC GRAVITY FOR ANALYSIS

F.1. Objective

To ensure that when the urine *Sample* does not meet the requirement for Suitable Specific Gravity for Analysis, appropriate procedures are followed.

F.2. Scope

The procedure begins with the DCO informing the *Athlete* that a further *Sample* is required and ends with the collection of a *Sample* that meets the requirements for Suitable Specific Gravity for Analysis, or appropriate follow-up action by NADO Italia if required.

F.3. Responsibility

F.3.1 The Sample Collection Authority is responsible for establishing procedures to ensure that a suitable *Sample* is collected, if the original *Sample* collected does not meet the requirement for Suitable Specific Gravity for Analysis.

F.3.2 The DCO is responsible for collecting additional *Samples* until a suitable *Sample* is obtained.

F.4. Requirements

F.4.1 The DCO shall determine that the requirements for Suitable Specific Gravity for Analysis have not been met.

F.4.2 The DCO shall inform the *Athlete* that they are required to provide a further *Sample*.

F.4.3 While waiting to provide a further *Sample*, the *Athlete* shall remain under continuous observation and shall be advised not to hydrate, since this may delay the production of a suitable *Sample*. In appropriate circumstances, further hydration after the provision of an unsuitable *Sample* may be pursued as a violation of Code Article 2.5.

F.4.4 When the *Athlete* is able to provide an additional *Sample*, the DCO shall repeat the procedures for *Sample* collection set out in Annex C - Collection of Urine *Samples*.

F.4.5 The DCO shall continue to collect additional *Samples* until the requirement for Suitable Specific Gravity for Analysis is met, or until the DCO determines that there are exceptional circumstances which mean it is impossible to continue with the Sample Collection Session. Such exceptional circumstances shall be documented accordingly by the DCO and described on the Supplementary Report Form. They may include:

- Athlete travel, if the athlete provides proof of travel (i.e., flight itinerary);
- Early morning competition, if it is getting late and the athlete is competing again in the morning;
- Closing of venue, if the venue is closing and there are no other location options available (i.e., athlete accommodation, etc.).

The Sample Collection Authority and DCOs should ensure they have adequate equipment to

comply with the requirements of this Annex. The DCO should wait as long as necessary to collect such additional Sample(s) with a Suitable Specific Gravity for Analysis.

- F.4.6 The DCO shall record that the *Samples* collected belong to a single *Athlete* and the order in which the *Samples* were provided.
- F.4.7 The DCO shall then continue with the Sample Collection Session in accordance with Annex C.4.17.
- F.4.8 The DCO shall send to the Laboratory for analysis all *Samples* which were collected, irrespective of whether or not they meet the requirement for Suitable Specific Gravity for Analysis.
- F.4.9 When two (2) *Samples* are collected from an *Athlete*, during the same Sample Collection Session, both Samples shall be analyzed by the Laboratory. In cases where three (3) or more Samples are collected during the same Sample Collection Session, the Laboratory shall prioritize and analyze the first and the subsequent collected *Sample* with the highest specific gravity, as recorded on the Doping Control form. The Laboratory, in conjunction with the Testing Authority, may determine if the other *Samples* need to be analyzed.

ANNEX G – SAMPLE COLLECTION PERSONNEL REQUIREMENTS

G.1 Objective

To ensure that Sample Collection Personnel have no conflict of interest and have adequate qualifications and experience to conduct Sample Collection Sessions.

G.2 Scope

Sample Collection Personnel requirements start with the development of the necessary competencies for Sample Collection Personnel and end with the provision of identifiable accreditation.

G.3 Responsibility

The Sample Collection Authority has the responsibility for all activities defined in this Annex.

G.4 Requirements - Qualifications and Training

G.4.1 The Sample Collection Authority shall:

- a Determine the necessary competence, eligibility and qualification requirements for the positions of DCO, Chaperone and BCO; and
- b Develop duty statements for all Sample Collection Personnel that outline their respective responsibilities. As a minimum:
 - Sample Collection Personnel shall not be *Minors*; and
 - BCOs shall have adequate qualifications and practical skills required to perform blood collection from a vein.

G.4.2 The Sample Collection Authority shall ensure that Sample Collection Personnel sign an agreement dealing with conflicts of interest, confidentiality and code of conduct.

G.4.3 Sample Collection Personnel shall not be appointed to a Sample Collection Session where they have an interest in the outcome of a Sample Collection Session. At a minimum, Sample Collection Personnel are deemed to have such an interest if they are:

- Involved in the participation or administration of the sport at the level for which *Testing* is being conducted;
- Related to, or involved in the personal affairs of, any *Athlete* who might provide a *Sample* at that Sample Collection Session;
- Have family members actively involved in the daily activities of the sport at the level for which

Testing is being conducted (e.g., administration, coaching, training, officiating, competitor, medical);

- Are engaged in business with, have a financial interest in or personal stake in a sport that has *Athletes* who are subject to *Testing*;
- Are drawing or likely to draw personal and/or professional gain or advantage directly or indirectly from a third party due to their own decisions taken in the fulfillment of their official functions; and/or
- Appear to have private or personal interests that detract from their ability to perform their duties with integrity in an independent and purposeful manner.

G.4.4 The Sample Collection Authority shall establish a system that ensures that Sample Collection Personnel are adequately trained to carry out their duties.

G.4.4.1 The training program for BCOs shall include, as a minimum, studies of all relevant requirements of the *Testing* process and familiarization with relevant standard precautions in healthcare settings.

G.4.4.2 The training program for DCOs shall include, as a minimum:

- Comprehensive theoretical training in those *Doping Control* activities relevant to the DCO position;
- Observation of all Sample Collection Session activities that are the responsibility of the DCO as set out in this *International Standard for Testing and Investigations*, preferably on-site; and
- The satisfactory performance of one complete Sample Collection Session on-site under observation by a qualified DCO or similar. The requirement related to the actual passing of a urine *Sample* shall not be included in the on-site observations.

G.4.4.3 The training program for Chaperones shall include all relevant requirements of the Sample Collection Session including but not limited to situations dealing with Failure to Comply, *Athletes* who are *Minors* and/or *Athletes* with impairments.

G.4.4.4 A Sample Collection Authority that collects *Samples* from *Athletes* who are of a different nationality to its Sample Collection Personnel (e.g., at an *International Event* or in an *Out-of-Competition* context) should ensure that such Sample Collection Personnel are adequately trained to carry out their duties in respect of such *Athletes*.

G.4.4.45 The Sample Collection Authority shall maintain records of education, training, skills and experience of all Sample Collection Personnel.

G.5 Requirements - Accreditation, re-accreditation and delegation

G.5.1 The Sample Collection Authority shall establish a system for accrediting and re-accrediting Sample Collection Personnel.

- G.5.2 The Sample Collection Authority shall ensure that Sample Collection Personnel have completed the training program and are familiar with the requirements of this *International Standard for Testing and Investigations* (including, where G.4.4.4 applies, in relation to the collection of *Samples* from *Athletes* who are of a different nationality than the Sample Collection Personnel) before granting accreditation.
- G.5.3 Accreditation shall only be valid for a maximum of two (2) years. Sample Collection Personnel shall be subject to an assessment (theoretical and/or practical) before being re- accredited and shall be required to repeat a full training program if they have not participated in *Sample* collection activities within the year prior to re-accreditation.
- G.5.4 Only Sample Collection Personnel who have an accreditation recognized by the Sample Collection Authority shall be authorized to conduct *Sample* collection activities on behalf of the Sample Collection Authority.
- G.5.5 The Sample Collection Authority shall develop a system to monitor the performance of Sample Collection Personnel during the period of accreditation, including defining and implementing criteria for revoking accreditation.
- G.5.2 DCOs may personally perform any activities involved in the Sample Collection Session, with the exception of blood collection unless particularly qualified, or they may direct a Chaperone to perform specified activities that fall within the scope of the Chaperone's authorized duties as determined by the Sample Collection Authority

ANNEX I – COLLECTION, STORAGE AND TRANSPORT OF BLOOD ATHLETE BIOLOGICAL PASSPORT SAMPLES

I.1. Objective

To collect an *Athlete's* blood *Sample*, intended for use in connection with the measurement of individual *Athlete* blood variables within the framework of the *Athlete* Biological Passport program, in a manner appropriate for such use.

I.2. Requirements

I.2.1 Planning shall consider the *Athlete's* whereabouts information to ensure *Sample* collection does not occur within two (2) hours of the *Athlete's* training, participation in Competition or other similar physical activity. If the *Athlete* has trained or competed less than two (2) hours before the time the *Athlete* has been notified of their selection, the DCO or other designated Sample Collection Personnel shall chaperone the *Athlete* until this two-hour period has elapsed.

I.2.2 If the *Sample* was collected within two (2) hours of training or Competition, the nature, duration and intensity of the exertion shall be recorded by the DCO to make this information available to the APMU and subsequently to the Experts.

I.2.3 Although a single blood *Sample* is sufficient within the framework of the *Athlete* Biological Passport, it is recommended to collect an additional B *Sample* for a possible subsequent analysis of Prohibited Substances and Prohibited Methods in whole blood (e.g., detection of Homologous Blood Transfusion (HBT) and/or Erythropoiesis Stimulating Agents (ESAs)).

I.2.4 For Out-of-Competition Testing, A and B urine *Samples* should be collected together with the blood *Sample(s)* in order to permit Analytical Testing for ESAs unless otherwise justified by a specific intelligent Testing strategy.

I.2.5 The *Sample* shall be refrigerated from its collection until its analysis with the exception of when the *Sample* is analyzed at the collection site without delay. The storage procedure is the DCO's responsibility.

I.2.6 The storage and transport device shall be capable of maintaining blood *Samples* at a cool temperature during storage. Whole blood *Samples* shall not be allowed to freeze at any time. In choosing the storage and transport device, the DCO shall take into account the time of storage, the number of *Samples* to be stored in the device and the prevailing environmental conditions (hot or cold temperatures). The storage device shall be one of the following:

- a) Refrigerator;
- b) Insulated cool box;
- c) Isotherm bag; or
- d) Any other device that possesses the capabilities mentioned above.

I.2.7 A temperature data logger shall be used to record the temperature from the collection to the analysis of the *Sample* except when the *Sample* is analyzed at the collection site without delay. The temperature data logger shall be able to:

- a) Record the temperature in degrees Celsius at least once per minute;

- b) Record time in GMT;
- c) Report the temperature profile over time in text format with one line per measurement following the format “YYYY-MM-DD HH:MM T”; and
- d) Have a unique ID of at least six characters.

I.2.8 Following notification to the *Athlete* that he/she has been selected for *Sample* collection and following the DCO/BCO's explanation of the *Athlete*'s rights and responsibilities in the *Sample* collection process, the DCO/BCO shall ask the *Athlete* to remain still, in a normal seated position, with feet on the floor for at least ten (10) minutes prior to providing a blood *Sample*.

I.2.9 The DCO/BCO shall collect and record the following additional information on an *Athlete* Biological Passport supplementary form, *Athlete* Biological Passport specific Doping Control form or other related report form to be signed by the *Athlete* and the DCO/BCO:

- a) Has the *Athlete* been seated for at least ten (10) minutes with their feet on the floor prior to blood collection?
- b) Was the *Sample* collected immediately following at least three (3) consecutive days of an intensive endurance Competition, such as a stage race in cycling?
- c) Has the *Athlete* had a training session or Competition in the two (2) hours prior to the blood collection?
- d) Did the *Athlete* train, compete or reside at an altitude greater than 1,500 meters within the prior two (2) weeks? If so, or if in doubt, the name and location of the place where the *Athlete* had been and the duration of their stay shall be recorded. The estimated altitude shall be entered, if known.
- e) Did the *Athlete* use any form of altitude simulation such as a hypoxic tent, mask, etc. during the prior two (2) weeks? If so, as much information as possible on the type of device and the manner in which it was used (e.g., frequency, duration, intensity) should be recorded.
- f) Did the *Athlete* receive any blood transfusion(s) during the prior three (3) months? Was there any blood loss due to accident, pathology or donation in the prior three (3) months? If so, the estimated volume should be recorded.
- g) Has the *Athlete* been exposed to any extreme environmental conditions during the last two (2) hours prior to blood collection, including any sessions in any artificial heat environment, such as a sauna? If so, the details should be recorded.

I.2.10 The DCO/BCO shall start the temperature data logger and place it in the storage device. It is important to start recording the temperature before *Sample* collection.

I.2.11 The storage device shall be located in the Doping Control Station and shall be kept secure.

I.2.12 The DCO/BCO instructs the *Athlete* to select the Sample Collection Equipment in accordance with Annex D.4.6. If the collection tube(s) are not pre-labelled, the DCO/BCO shall label them with a unique *Sample* code number prior to the blood being drawn and the *Athlete* shall check that the code numbers match.

I.3. The *Sample* Collection Procedure

I.3.1 The *Sample* collection procedure for the collection of blood for the purposes of the *Athlete* Biological Passport is consistent with the procedure set out in Annex D.4., including the ten (10) minute (or more) seated period, with the following additional elements:

- a) The BCO ensures that the collection tubes were filled appropriately; and
- b) After the blood flow into the tube ceases, the BCO removes the tube from the holder and homogenizes the blood in the tube manually by inverting the tube gently at least three (3) times.

I.3.2 The *Athlete* and the DCO/BCO sign the Doping Control and *Athlete* Biological Passport supplementary form(s), when applicable.

I.3.3 The blood *Sample* is sealed and deposited in the storage device containing the temperature data logger.

I.4. **Transportation Requirements**

I.4.1 Blood *Samples* shall be transported in a device that maintains the integrity of *Samples* over time, due to changes in external temperature.

I.4.2 The transport procedure is the DCO's responsibility. The transport device shall be transported by secure means using a Sample Collection Authority authorized transport method.

I.4.3 The integrity of the Markers used in the haematological module of the *Athlete* Biological Passport is guaranteed when the Blood Stability Score (BSS) remains below eighty-five (85), where the BSS is computed as:

$$BSS = 3 * T + CAT$$

with CAT being the Collection to Analysis Time (in hours), and T the average Temperature (in degrees Celsius) measured by the data logger between *Sample* collection and analysis.

I.4.4 Within the framework of the BSS, the following table can be used by the DCO/BCO to estimate the maximal transport time to a Laboratory or WADA- Approved Laboratory for the *Athlete* Biological Passport, called the Collection to Reception Time (CRT), for a given average temperature T:

T [°C]	CRT [h]
15	35
12	41
10	46
9	48
8	50
7	53
6	55
5	58
4	60

- I.4.5 The DCO/BCO shall as soon as possible transport the *Sample* to a Laboratory or WADA-Approved Laboratory for the *Athlete* Biological Passport.
- I.4.6 The Testing Authority or Sample Collection Authority shall report without delay into *ADAMS*:
- a) The Doping Control form as per ISTI Article 4.9.1 b);
 - b) The *Athlete* Biological Passport supplementary form, and/or the additional information specific to the *Athlete* Biological Passport collected on a related report form;
 - c) In the Chain of Custody, the temperature data logger ID (without any time reference) and the time zone of the Testing location in GMT.

Definitions

Defined Terms from the *Code* and from the *ADSC*

ADAMS: The Anti-Doping Administration and Management System is a Web-based database management tool for data entry, storage, sharing, and reporting designed to assist stakeholders and WADA in their anti-doping operations in conjunction with data protection legislation.

Adverse Analytical Finding: A report from a WADA-accredited laboratory or other WADA- approved laboratory that, consistent with the International Standard for Laboratories, establishes in a *Sample* the presence of a Prohibited Substance or its Metabolites or Markers or evidence of the Use of a Prohibited Method.

Adverse Passport Finding: A report identified as an *Adverse Passport Finding* as described in the applicable International Standards.

Anti-Doping Organization: WADA or a Signatory that is responsible for adopting rules for initiating, implementing or enforcing any part of the Doping Control process. This includes, for example, the International Olympic Committee, the International Paralympic Committee, other Major Event Organizations that conduct Testing at their Events, International Federations, and National Anti-Doping Organizations.

Anti-Doping Sport Code (ADSC): The Code, adopted by NADO Italia, implementing the *World Anti-Doping Code* and the *International Standards*.

Athlete: Any *Person* who Competes in sport under the aegis of the relevant International Federation and/or the Italian National Olympic Committee (CONI) and Italian Paralympic Committee (IPC).

Athlete Biological Passport: The program and methods of gathering and collating data as described in the International Standard for Testing and Investigations and International Standard for Laboratories.

Athlete Support Personnel: Any coach, trainer, manager, agent, team staff, official, medical, paramedical personnel, parent or any other *Person* working with, treating or assisting an *Athlete* participating in or preparing for sports Competition.

Attempt: Purposely engaging in conduct that constitutes a substantial step in a course of conduct planned to culminate in the commission of an anti-doping rule violation. Provided, however, there shall be no anti-doping rule violation based solely on an Attempt to commit a violation if the *Person* renounces the Attempt prior to it being discovered by a third party not involved in the Attempt.

Atypical Finding: A report from a WADA-accredited laboratory or other WADA-approved laboratory which requires further investigation as provided by the International Standard for Laboratories or related Technical Documents prior to the determination of an *Adverse Analytical Finding*.

Atypical Passport Finding: A report described as an Atypical Passport Finding as described in the applicable International Standards.

CAS: The Court of Arbitration for Sport.

Code: The World Anti-Doping Code.

Competition: A single race, match, game or singular sport contest. For example, a basketball game or the finals of the Olympic 100-meter race in athletics. For stage races and other sport contests where prizes are awarded on a daily or other interim basis, the distinction between a Competition and an Event will be as provided in the rules of the applicable International Federation.

Consequences of Anti-Doping Rule Violations (“Consequences”): An *Athlete’s* or other Person’s violation of an anti-doping rule may result in one or more of the following: (a) Disqualification means the *Athlete’s* results in a particular Competition or Event are invalidated, with all resulting Consequences including forfeiture of any medals, points and prizes; (b) Ineligibility means the *Athlete* or other Person is barred on account of an anti-doping rule violation for a specified period of time from participating in any Competition or other activity or funding as provided in *Code* Article 10.14.1; (c) Provisional Suspension means the *Athlete* or other Person is barred temporarily from participating in any Competition or activity prior to the final decision at a hearing conducted under *Code* Article 8; (d) Financial Consequences means a financial sanction imposed for an anti-doping rule violation or to recover costs associated with an anti-doping rule violation; and (e) Public Disclosure means the dissemination or distribution of information to the general public or Persons beyond those Persons entitled to earlier notification in accordance with *Code* Article 14. Teams in Team Sports may also be subject to Consequences as provided in *Code* Article 11.

Decision Limit: The value of the result for a Threshold Substance in *Sample*, above which an *Adverse Analytical Finding* shall be reported, as defined in the International Standard for Laboratories.

Delegated Third Parties: Any Person to which an Anti-Doping Organization delegates any aspect of Doping Control or anti-doping Education programs including, but not limited to, third parties or other Anti-Doping Organizations that conduct *Sample* collection or other Doping Control services or anti-doping Educational programs for the Anti-Doping Organization, or individuals serving as independent contractors who perform Doping Control services for the Anti-Doping Organization (e.g., non-employee Doping Control Officers or Chaperones). This definition does not include CAS.

Doping Control: All steps and processes from test distribution planning through to ultimate disposition of any appeal and the enforcement of Consequences, including all steps and processes in between, including but not limited to, Testing, investigation, whereabouts, TUEs, *Sample* collection and handling, laboratory analysis, *Results Management*, hearings and appeals, and investigations or proceedings relating to violations of *Code* Article 10.14 (Status During Ineligibility or Provisional Suspension).

Education: The process of learning to instill values and develop behaviors that foster and protect the spirit of sport, and to prevent intentional and unintentional doping.

Event: A series of individual Competitions conducted together under one ruling body (e.g., the Olympic Games, World Championships of an International Federation, or Pan American Games).

Event Venues: Those venues so designated by the ruling body for the Event.

In-Competition: The period commencing at 11:59 p.m. on the day before a Competition in which the *Athlete* is scheduled to participate through the end of such Competition and the *Sample* collection process related to such Competition. Provided, however, WADA may approve, for a particular sport, an alternative definition if an International Federation provides a compelling justification that a different definition is necessary for its sport; upon such approval by WADA, the alternative definition shall be followed by all Major Event Organizations for that particular sport.

Independent Observer Program: A team of observers and/or auditors, under the supervision of WADA, who observe and provide guidance on the Doping Control process prior to or during certain Events and report on their observations as part of WADA's compliance monitoring program.

Ineligibility: See Consequences of Anti-Doping Rule Violations above.

International Event: An Event or Competition where the International Olympic Committee, the International Paralympic Committee, an International Federation, a Major Event Organization, or another international sport organization is the ruling body for the Event or appoints the technical officials for the Event.

International-Level Athlete: *Athletes* who compete in sport at the international level, as defined by each International Federation, consistent with the International Standard for Testing and Investigations.

International Standard: A standard adopted by WADA in support of the Code. Compliance with an International Standard (as opposed to another alternative standard, practice or procedure) shall be sufficient to conclude that the procedures addressed by the International Standard were performed properly. International Standards shall include any Technical Documents issued pursuant to the International Standard.

Marker: A compound, group of compounds or biological variable(s) that indicates the Use of a Prohibited Substance or Prohibited Method.

Minor: A natural Person who has not reached the age of eighteen years.

National Anti-Doping Organization: The entity(ies) designated by each country as possessing the primary authority and responsibility to adopt and implement anti-doping rules, direct the collection of *Samples*, manage test results and conduct *Results Management* at the national level. If this designation has not been made by the competent public authority(ies), the entity shall be the country's National Olympic Committee or its designee.

National Event: A sport Event or Competition involving International- or National-Level *Athletes* that is not an International Event.

National-Level Athlete: An *Athlete* included in the national RTP; *Athletes* included in the Club Olimpico (who receive funding from Sports movement); an *Athlete* who currently or in the last six (6) months has represented Italy at senior level; an *Athlete* who

has been selected to represent Italy in International *Events* or Competitions, not classified as International-Level *Athlete* by the relevant International Federation.

National Olympic Committee: The organization recognized by the International Olympic Committee. The term National Olympic Committee shall also include the National Sport Confederation in those countries where the National Sport Confederation assumes typical National Olympic Committee responsibilities in the anti-doping area. In Italy, the *National Olympic Committee* is *Comitato Olimpico Nazionale Italiano* (CONI).

Out-of-Competition: Any period which is not In-Competition.

Person: A natural Person or an organization or other entity.

Prohibited Method: Any method so described on the Prohibited List.

Prohibited Substance: Any substance, or class of substances, so described on the Prohibited List.

Protected Person: An *Athlete* or other natural Person who at the time of the anti-doping rule violation: (i) has not reached the age of sixteen (16) years; (ii) has not reached the age of eighteen (18) years and is not included in any *Registered Testing Pool* and has never competed in any International Event in an open category; or (iii) for reasons other than age, has been determined to lack legal capacity under applicable national legislation.

Provisional Suspension: See Consequences of Anti-Doping Rule Violations above.

Recreational Athlete: In Italy, *Recreational Athlete* is any *Person* member of a Sport Promotion Entity, or any *Person* who takes part in local *Competitions* or competes at lower level *Team Sports*.

In any case, *Recreational Athlete* does not include who, within the five (5) years prior to committing any anti-doping rule violation: (i) has been an *International-Level Athlete* (as defined by each International Federation consistent with the *International Standard for Testing and Investigations*) or *National-Level Athlete* (as defined by NADO Italia or other *National Anti-Doping Organization* consistent with the *International Standard for Testing and Investigations*); (ii) has represented Italy or any other country in an *International Event* in an open category; (iii) or has been included within any *Registered Testing Pool* or other whereabouts information pool maintained by any International Federation, NADO Italia or other *National Anti-Doping Organization*.

Registered Testing Pool: The pool of highest-priority *Athletes* established separately at the international level by International Federations and at the national level by National Anti-Doping Organizations, who are subject to focused In-Competition and Out-of-Competition Testing as part of that International Federation's or National Anti-Doping Organization's Test Distribution Plan and therefore are required to provide whereabouts information as provided in Article 5.5 and the *International Standard for Testing and Investigations*. In Italy, NADO Italia's *Registered Testing Pool* is defined as set out in *ADSC* Article 6.5.

Results Management: The process encompassing the timeframe between notification as per Article 5 of the International Standard for Results Management, or in certain cases (e.g., Atypical Finding, *Athlete Biological Passport*, Whereabouts Failure), such pre-

notification steps expressly provided for in Article 5 of the *International Standard for Results Management*, through the charge until the final resolution of the matter, including the end of the hearing process at first instance or on appeal (if an appeal was lodged).

Sample or Specimen: Any biological material collected for the purposes of Doping Control.

Signatories: Those entities accepting the *Code* and agreeing to implement the *Code*, as provided in *Code* Article 23.

Substantial Assistance: For purposes of *Code* Article 10.7.1, a Person providing *Substantial Assistance* must: (1) fully disclose in a signed written statement or recorded interview all information he or she possesses in relation to anti-doping rule violations or other proceeding described in *Code* Article 10.7.1.1 and (2) fully cooperate with the investigation and adjudication of any case or matter related to that information, including, for example, presenting testimony at a hearing if requested to do so by an Anti-Doping Organization or hearing panel. Further, the information provided must be credible and must comprise an important part of any case or proceeding which is initiated or, if no case or proceeding is initiated, must have provided a sufficient basis on which a case or proceeding could have been brought.

Tampering: Intentional conduct which subverts the Doping Control process but which would not otherwise be included in the definition of Prohibited Methods. *Tampering* shall include, without limitation, offering or accepting a bribe to perform or fail to perform an act, preventing the collection of a Sample, affecting or making impossible the analysis of a Sample, falsifying documents submitted to an Anti-Doping Organization or TUE committee or hearing panel, procuring false testimony from witnesses, committing any other fraudulent act upon the Anti-Doping Organization or hearing body to affect Results Management or the imposition of Consequences, and any other similar intentional interference or Attempted interference with any aspect of Doping Control.

Target Testing: Selection of specific *Athletes* for Testing based on criteria set forth in the *International Standard for Testing and Investigations*.

Team Sport: A sport in which the substitution of players is permitted during a *Competition*.

Technical Document: A document adopted and published by WADA from time to time containing mandatory technical requirements on specific anti-doping topics as set forth in an *International Standard*.

Testing: The parts of the Doping Control process involving test distribution planning, Sample collection, Sample handling, and Sample transport to the Laboratory.

WADA: The World Anti-Doping Agency.

Defined terms from the International Standard for Laboratories:

Adaptive Model: A mathematical model designed to identify unusual longitudinal results from *Athletes*. The model calculates the probability of a longitudinal profile of Marker

values, assuming that the *Athlete* has a normal physiological condition.

Analytical Testing: The parts of the Doping Control process performed at the Laboratory, which include Sample handling, analysis and reporting of results.

Athlete Passport Management Unit (APMU): A unit composed of a Person or Persons that is responsible for the timely management of *Athlete* Biological Passports in ADAMS on behalf of the Passport Custodian.

Confirmation Procedure (CP): An Analytical Testing Procedure that has the purpose of confirming the presence and/or, when applicable, confirming the concentration/ratio/score and/or establishing the origin (exogenous or endogenous) of one or more specific Prohibited Substances, Metabolite(s) of a Prohibited Substance, or Marker(s) of the Use of a Prohibited Substance or Prohibited Method in a Sample.

Laboratory(ies): (A) WADA-accredited laboratory(ies) applying Test Methods and processes to provide evidentiary data for the detection and/or identification of Prohibited Substances or Prohibited Methods on the Prohibited List and, if applicable, quantification of a Threshold Substance in Samples of urine and other biological matrices in the context of Doping Control activities.

WADA-Approved Laboratory(-ies) for the Athlete Biological Passport: Laboratory(-ies) not otherwise accredited by WADA which apply Analytical Methods and processes in support of the hematological module of the ABP program and in accordance with the criteria for approval of non-accredited laboratories for the ABP.

Defined terms from the International Standard for Results Management:

Failure to Comply: A term used to describe anti-doping rule violations under *Code* Articles 2.3 and/or 2.5.

Filing Failure: A failure by the *Athlete* (or by a third party to whom the *Athlete* has delegated the task) to make an accurate and complete Whereabouts Filing that enables the *Athlete* to be located for Testing at the times and locations set out in the Whereabouts Filing or to update that Whereabouts Filing where necessary to ensure that it remains accurate and complete, all in accordance with Article 4.8 of the International Standard for Testing and Investigations and Annex B of the International Standard for Results Management.

Missed Test: A failure by the *Athlete* to be available for Testing at the location and time specified in the 60-minute time slot identified in their Whereabouts Filing for the day in question, in accordance with Article 4.8 of the International Standard for Testing and Investigations and Annex B of the International Standard for Results Management.

Passport: A collation of all relevant data unique to an individual *Athlete* that may include longitudinal profiles of Markers, heterogeneous factors unique to that particular *Athlete* and other relevant information that may help in the evaluation of Markers.

Passport Custodian: The Anti-Doping Organization responsible for Results Management of that *Athlete's* Passport and for sharing any relevant information associated to that *Athlete's* Passport with other Anti-Doping Organization(s).

Results Management Authority: The Anti-Doping Organization responsible for conducting Results Management in a given case.

Whereabouts Failure: A Filing Failure or a Missed Test.

Defined terms from the International Standard for the Protection of Privacy and Personal Information:

Processing (and its cognates, Process and Processed): Collecting, accessing, retaining, storing, disclosing, transferring, transmitting, amending, deleting or otherwise making use of Personal Information.

Defined terms specific to the International Standard for Testing and Investigations:

Blood Collection Officer (or BCO): An official who is qualified and has been authorized by the Sample Collection Authority to collect a blood Sample from an *Athlete*.

Chain of Custody: The sequence of individuals or organizations who have responsibility for the custody of a Sample from the provision of the Sample until the Sample has been delivered to the Laboratory for analysis.

Chaperone: An official who is suitably trained and authorized by the Sample Collection Authority to carry out specific duties including one or more of the following (at the election of the Sample Collection Authority); notification of the *Athlete* selected for Sample collection; accompanying and observing the *Athlete* until arrival at the Doping Control Station; accompanying and/or observing *Athletes* who are present in the Doping Control Station; and/or witnessing and verifying the provision of the Sample where the training specifically qualifies them to do so.

Code Article 2.4 Whereabouts Requirements: The whereabouts requirements set out in Article 4.8 of the International Standard for Testing and Investigations, which apply to *Athletes* who are included in the Registered Testing Pool of an International Federation or a National Anti-Doping Organization.

Doping Control Coordinator: An Anti-Doping Organization or a Delegated Third Party that coordinates any aspect of Doping Control on behalf of an Anti-Doping Organization. The Anti-Doping Organization always remains ultimately responsible under the Code for compliance with the requirements of the International Standard for Testing and Investigations, Therapeutic Use Exemptions, Protection of Privacy and Personal Information, and Results Management.

Doping Control Officer (or DCO): An official who has been trained and authorized by the Sample Collection Authority to carry out the responsibilities given to DCOs in the International Standard for Testing and Investigations.

Doping Control Station: The location where the Sample Collection Session will be conducted in accordance with Article 6.3.2 of the International Standard for Testing and Investigations.

Expert: The Expert(s) and/or Expert Panel, with knowledge in the concerned field, chosen by the Anti-Doping Organization and/or *Athlete* Passport Management Unit, who are responsible for providing an evaluation of the Passport. The Expert must be external to the Anti-Doping Organization.

For the Haematological Module, the Expert Panel should consist of at least three (3) Experts who have qualifications in one or more of the fields of clinical and laboratory haematology, sports medicine or exercise physiology, as they apply to blood doping. For the Steroidal Module, the Expert Panel should be composed of at least three (3) individuals with qualifications in the fields of laboratory steroid analysis, steroid doping and metabolism and/or clinical endocrinology. For both modules, an Expert Panel should consist of Experts with complementary knowledge such that all relevant fields are represented. The Expert Panel may include a pool of at least three (3) appointed Experts and any additional ad hoc Expert(s) who may be required upon request of any of the appointed Experts or by the *Athlete* Passport Management Unit of the Anti-Doping Organization.

In-Competition Date: As described in Article 4.8.8.4 of the International Standard for Testing and Investigations.

No Advance Notice Testing: Sample collection that takes place with no advance warning to the *Athlete* and where the *Athlete* is continuously chaperoned from the moment of notification through Sample provision.

Random Selection: Selection of *Athletes* for Testing which is not *Target Testing*.

Risk Assessment: The assessment of risk of doping in a sport or sports discipline conducted by an Anti-Doping Organization in accordance with Article 4.2 of the International Standard for Testing and Investigations.

Sample Collection Authority: The organization that is responsible for the collection of Samples in compliance with the requirements of the International Standard for Testing and Investigations, whether (1) the Testing Authority itself; or (2) a Delegated Third Party to whom the authority to conduct Testing has been granted or sub-contracted. The Testing Authority always remains ultimately responsible under the Code for compliance with the requirements of the International Standard for Testing and Investigations relating to collection of Samples.

Sample Collection Equipment: A and B bottles, kits or containers, collection vessels, tubes or other apparatus used to collect, hold or store the Sample at any time during and after the Sample Collection Session that shall meet the requirements of Article 6.3.4 of the International Standard for Testing and Investigations.

Sample Collection Personnel: A collective term for qualified officials authorized by the Sample Collection Authority to carry out or assist with duties during the Sample Collection Session.

Sample Collection Session: All of the sequential activities that directly involve the *Athlete* from the point that initial contact is made until the *Athlete* leaves the Doping Control Station after having provided their Sample(s).

Suitable Specific Gravity for Analysis: For Samples with a minimum volume of 90mL

and less than 150mL, specific gravity measured at 1.005 or higher with a refractometer, or 1.010 or higher with lab sticks. For Samples with a volume of 150mL and above, specific gravity measured at 1.003 or higher with a refractometer only.

Suitable Volume of Urine for Analysis: A minimum of 90 mL, whether the Laboratory will be analyzing the Sample for all or only some Prohibited Substances or Prohibited Methods.

Tamper Evident: Refers to having one or more indicators or barriers to entry incorporated into or, if applicable, included with the Sample Collection Equipment, which, if breached or missing or otherwise compromised, can provide visible evidence that *Tampering* or Attempted *Tampering* of Sample Collection Equipment has occurred.

Team Activity/Activities: Sporting activities carried out by *Athletes* on a collective basis as part of a team (e.g., training, travelling, tactical sessions) or under the supervision of the team (e.g., treatment by a team doctor).

Technical Document for Sport Specific Analysis (TDSSA): The Technical Document which establishes minimum levels of analysis that Anti-Doping Organizations must apply to sports and sport disciplines for certain Prohibited Substances and/or Prohibited Methods, which are most likely to be abused in particular sports and sport disciplines.

Test(s): Any combination of Sample(s) collected (and analyzed) from a single *Athlete* in a single Sample Collection Session.

Test Distribution Plan (TDP): A document written by an Anti-Doping Organization that plans Testing on *Athletes*, in accordance with the requirements of Article 4 of the International Standard for Testing and Investigations.

Testing Authority: The Anti-Doping Organization that authorizes Testing on *Athletes* it has authority over. It may authorize a Delegated Third Party to conduct Testing pursuant to the authority of and in accordance with the rules of the Anti-Doping Organization. Such authorization shall be documented. The Anti-Doping Organization authorizing Testing remains the Testing Authority and ultimately responsible under the Code to ensure the Delegated Third Party conducting the Testing does so in compliance with the requirements of the International Standard for Testing and Investigations.

Unsuccessful Attempt Report: A detailed report of an unsuccessful attempt to collect a Sample from an *Athlete* in a *Registered Testing Pool* or Testing pool setting out the date of the attempt, the location visited, the exact arrival and departure times at the location, the steps taken at the location to try to find the *Athlete* (including details of any contact made with third parties), and any other relevant details about the attempt.

Whereabouts Filing: Information provided by or on behalf of an *Athlete* in a *Registered Testing Pool* (or Testing pool if applicable) that sets out the *Athlete's* whereabouts during the following quarter, in accordance with Article 4.8 of the International Standard for Testing and Investigations.